



2026 Prior Authorization (PA) Criteria

Certain drugs require prior authorization from EmblemHealth Medicare HMO/PPO Medicare Plans. This means that your doctor must contact us to get approval before prescribing the drug to you. If your doctor does not get prior approval, the drug may not be covered.

This list also includes drugs that may be covered under Medicare Part B or Part D depending on how the drugs are used or administered. If your drug is on this list, your doctor should call us and to provide information describing the use and administration of the drug, so we can advise on whether the drug will be covered.

To see if your drug is on the list, refer to the table of contents located on the next page of this document for the medication you are looking for.

2026 PRIOR AUTHORIZATION CRITERIA

TABLE OF CONTENTS

Abiraterone Acetate	211
Abirtega	211
Accutane	124
Actemra.....	42
Actemra Actpen	42
Actimmune.....	10
Acyclovir	11
Adempas	187
Aimovig	12
Akeega.....	211
Alcohol Swabs	13
Alecensa	211
Alosetron Hcl.....	14
Alunbrig.....	211
Ambrisentan.....	189
Amnesteem	124
Arcalyst.....	25
Arikayce.....	26
Aripiprazole	23
Aripiprazole Odt.....	23
Armodafinil	27
Asenapine Maleate Sl.....	23
Atovaquone.....	30
Attruby	31
Augtyro.....	211
Austedo	32
Austedo Xr.....	32
Austedo Xr Patient Titration Kit	32
Avmapki Fakzynja Co-Pack.....	211
Avonex	147
Avonex Pen	147
Ayvakit.....	211
Balversa	211
Benlysta SC.....	34
Besremi	211
Betaseron	148
Bexarotene Capsules.....	211
Bexarotene Gel	40
Bonsity	235
Bosentan	191
Bosulif	211

Braftovi.....	211
Brukina	211
Budesonide Dr (Entocort)	70
Budesonide Er (Uceris).....	71
Bysanti.....	23
Cabometyx	211
Calquence.....	211
Caprelsa.....	211
Carglumic Acid	72
Cayston	73
Cerezyme	105
Chenodal	74
Chlorpromazine Hcl.....	23
Chorionic Gonadotropin	75
Cinacalcet Hcl.....	76
Claravis	124
Clobazam.....	35
Clorazepate Dipotassium	36
Clozapine.....	23
Clozapine Odt.....	23
Cobenfy	77
Cobenfy Starter Pack	77
Cometriq	211
Copiktra.....	211
Corlanor	80
Cosentyx.....	44
Cosentyx Sensoready Pen	44
Cosentyx Unoready.....	44
Cotellic	211
Cresemba	81
Crysvita.....	82
Cyproheptadine Hcl	115
Cystagon.....	85
Cystaran	84
Dalfampridine Er	86
Danazol	16
Danziten	211
Dasatinib	211
Daurismo	211
Deferasirox (Exjade).....	122
Deferasirox (Jadenu)	123
Depo-Testosterone	17
Dexmethylphenidate Hcl (Focalin).....	102
Diazepam	37
Diazepam Intensol	37
Diclofenac Sodium (Pennsaid)	240
Diclofenac Sodium Gel 3%	239
Dicyclomine Hcl.....	115

Dihydroergotamine Mesylate Spray	144
Dimethyl Fumarate	149
Dimethyl Fumarate Starterpack.....	149
Diphenoxylate/Atropine	115
Droxidopa.....	87
Dupixent.....	88
ElELYso	106
Eligard	132
Eltrombopag	185
Emgality.....	91
Emsam.....	92
Enbrel	46
Enbrel Mini.....	46
Enbrel Sureclick.....	46
Ensacove	211
Entyvio Pen	48
Epidiolex.....	94
Erivedge	211
Erleada	211
Erlotinib Hcl.....	211
Eucrisa	28
Everolimus.....	211
Fanapt	23
Fanapt Pack A.....	23
Fanapt Pack C.....	23
Fentanyl Citrate Oral Transmucosal.....	99
Fentanyl Patch	166
Fingolimod Hcl	150
Fintepla	100
Firmagon	119
Flucytosine	101
Fluphenazine Decanoate	23
Fluphenazine Hcl.....	23
Fotivda	211
Fruzaqla.....	211
Gammagard Liquid.....	103
Gammagard Liquid Erc.....	103
Gamunex-C.....	103
Gauze Pads.....	108
Gavreto	211
Gefitinib	211
Gilotrif	211
Glatiramer Acetate.....	151
Glatopa.....	151
Gomekli	211
Granix.....	79
Hadlima	49
Hadlima Pushtouch	49

Haegarda	111
Haloperidol.....	23
Haloperidol Decanoate	23
Haloperidol Lactate.....	23
Hernexeos	211
Hydroxyzine Hcl	115
Hyrnuo	211
Ibrance	211
Ibtrozi	211
Icatibant Acetate.....	113
Iclusig	211
Idhifa	211
Imatinib Mesylate	212
Imbruvica	212
Imiquimod Cream 5%	116
Imkeldi.....	212
Inbrija	117
Ingrezza	118
Inluriyo	212
Inlyta	212
Inqovi	212
Inrebic	212
Insulin Pen Needle	120
Insulin Syringe/Needle	121
Isotretinoin.....	124
Itovebi	212
Ivabradine Hcl	80
Ivermectin Tablet	125
Iwilfin.....	212
Jakafi	212
Jaypirca	212
Jubbonti.....	126
Kalydeco	130
Kerendia	131
Kesimpta	152
Kisqali	212
Kisqali Femara	212
Komzifti	212
Koselugo.....	212
Krazati	212
Lapatinib Ditosylate	212
Lazcluze	212
Lenalidomide.....	212
Lenvima	212
Leuprolide Acetate.....	132
L-glutamine	133
Lidocaine Patch	134
Lidocaine/Prilocaine.....	135

Lidocan	134
Lifyorli	212
Linezolid	136
Lonsurf	212
Lorazepam.....	38
Lorazepam Intensol.....	38
Lorbrena	212
Loxapine	23
Lumakras	212
Lupron Depot	132
Lupron Depot-Ped.....	132
Lurasidone Hcl.....	23
Lybalvi	23
Lynparza	212
Lytgobi.....	212
Matulane	212
Mavyret.....	138
Mekinist	212
Mektovi	212
Memantine Hcl.....	139
Memantine Hcl Titration Pak	139
Methylphenidate Hcl (Methylin).....	140
Methylphenidate Hcl (Ritalin)	207
Methylphenidate Hcl Er Tablet	141
Miebo	142
Mifepristone	143
Miglustat	232
Modafinil	145
Modeyso	212
Molindone Hcl.....	23
Morphine Sulfate Er	168
Mounjaro	146
Nerlynx	212
Nexletol.....	155
Nexlizet	157
Nilotinib.....	212
Ninlaro.....	212
Nintedanib	163
Nubeqa.....	212
Nuedexta.....	159
Nuplazid	160
Nurtec	161
Octreotide Acetate.....	224
Odomzo.....	212
Ogsiveo.....	212
Ojemda.....	212
Ojjaara.....	212
Olanzapine	23

Olanzapine Odt	23
Omnipod Kit	164
Omnipod Pods.....	164
Omnitrope.....	109
Onureg	212
Opipza	23
Orencia	51
Orencia Clickject.....	51
Orenitram.....	193
Orenitram Titration Kit.....	193
Orgovyx	212
Orkambi	172
Orserdu	212
Osenvelt	173
Otezla	175
Otezla Xr.....	177
Ozempic Inj	179
Ozempic Tab.....	209
Paliperidone Er.....	23
Panretin.....	180
Pazopanib Hcl.....	212
Pegasys.....	181
Pemazyre.....	212
Perphenazine	23
Pimozide.....	23
Piqray	213
Pirfenidone.....	182
Plegridy	153
Plegridy Starter Pack	153
Pomalidomide.....	213
Posaconazole	183
Posaconazole Dr.....	183
Pregnyl	75
Procrit.....	95
Prolastin-C.....	15
Primethamine.....	200
Pyrukynd	201
Pyrukynd Taper Pack.....	201
Pyzchiva.....	53
Qinlock	213
Quetiapine Fumarate	23
Quetiapine Fumarate Er.....	23
Quinine Sulfate	202
Repatha	203
Repatha Sureclick.....	203
Retacrit.....	97
Retevmo	213
Revcovi	205

Revuforj.....	213
Rexulti	23
Rezdiffra	206
Rezlidhia	213
Rinvoq Lq.....	55
Rinvoq Tablet	56
Risperidone	23
Risperidone Odt	23
Roflumilast	208
Romvimza.....	213
Rozlytrek	213
Rubraca	213
Rybelsus	209
Rydapt	213
Sajazir	113
Sapropterin Dihydrochloride	210
Scemblix	213
Scopolamine.....	115
Secuado.....	23
Signifor	216
Sildenafil Citrate.....	195
Simlandi.....	60
Sivextro	218
Skyrizi	62
Skyrizi Pen	62
Sodium Oxybate.....	220
Sodium Phenylbutyrate	249
Somatuline Depot	222
Somavert.....	226
Sorafenib	213
Steqeyma.....	64
Stivarga	213
Stoboclo	227
Strensiq	230
Sunitinib Malate.....	213
Sympazan	39
Tabrecta	213
Tacrolimus.....	29
Tadalafil 2.5Mg, 5Mg	33
Tadalafil Tablet 20Mg	197
Tafinlar	213
Tagrisso	213
Talzenna	213
Tasimelteon.....	234
Tazarotene	241
Tepmetko	213
Teriparatide.....	235
Testosterone	21

Testosterone Cypionate	17
Testosterone Enanthate	19
Testosterone Pump.....	21
Tetrabenazine	237
Thalomid	213
Thioridazine Hcl.....	23
Thiothixene	23
Tibsovo	213
Tobramycin Neb.....	238
Tolvaptan (Jynarque).....	129
Torpenz	213
Tramadol Hcl Er	170
Trelstar Mixject	243
Tremfya	66
Tretinoin Capsule	213
Tretinoin Cream, Gel.....	242
Tridacaine Patch.....	134
Trientine Hcl.....	244
Trifluoperazine Hcl	23
Trikafta	245
Trulicity	246
Truqap.....	213
Tukysa	213
Turalio	213
Tyenne.....	68
Tymlos.....	247
Ustekin-Aekn.....	58
Valchlor	250
Vanflyta	213
Venclexta.....	213
Venclexta Starting Pack.....	213
Veozah.....	252
Versacloz	23
Verzenio	213
Vitrakvi	213
Vizimpro	213
Vonjo	213
Voranigo.....	213
Voriconazole	253
Vosevi.....	255
Vowst	256
Vpriv	107
Vumerity	154
Welireg.....	213
Winrevair	199
Wyost	257
Xalkori	213
Xdemvy	259

Xermelo.....	260
Xifaxan 550Mg	261
Xiidra	165
Xolair	262
Xospata	213
Xpovio	213
Xtandi	213
Yargesa	232
Zejula.....	213
Zelboraf	213
Zelvysia.....	210
Zenatane	124
Ziprasidone Mesylate.....	23
Zokinvy	265
Zolanza	213
Ztalmy	266
Zydelig.....	213
Zykadia	213

Prior Authorization Group Description:

Actimmune PA

Drug Name(s)

Actimmune

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Acyclovir Topical PA

Drug Name(s)

Acyclovir

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Aimovig PA

Drug Name(s)

Aimovig

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of migraine AND
2. The requested agent is being used for migraine prophylaxis AND
3. Patient has 4 or more migraine headache days per month AND
4. Patient will NOT be using the requested agent in combination with another calcitonin gene-related peptide (CGRP) agent for migraine prophylaxis

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of migraine AND
3. The requested agent is being used for migraine prophylaxis AND
4. Patient has had clinical benefit with the requested agent AND
5. Patient will NOT be using the requested agent in combination with another calcitonin gene-related peptide (CGRP) agent for migraine prophylaxis

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Alcohol Swabs PA

Drug Name(s)

Alcohol Swabs

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

This program will be implemented as a dynamic PA.

Criteria for approval require BOTH of the following:

1. The requested medical supply product will be used in the delivery of insulin to the body AND
2. Patient's medication history includes use of insulin within the past 180 days

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Alosetron PA

Drug Name(s)

Alosetron Hcl

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of irritable bowel syndrome with severe diarrhea (IBS-D) AND
2. Patient's sex is female AND
3. Patient exhibits at least ONE of the following:
 - a. Frequent and severe abdominal pain/discomfort OR
 - b. Frequent bowel urgency or fecal incontinence OR
 - c. Disability or restriction of daily activities due to IBS AND
4. Prescriber has ruled out anatomic or biochemical abnormalities of the gastrointestinal tract

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Alpha-1-Proteinase Inhibitor PA – Prolastin-C

Drug Name(s)

Prolastin-C

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of alpha-1 antitrypsin deficiency (AATD) with clinically evident emphysema AND
2. Patient has a pre-treatment serum alpha-1 antitrypsin (AAT) level less than 11 micromol/L (80 mg/dL by immunodiffusion or 57 mg/dL using nephelometry) AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of alpha-1 antitrypsin deficiency (AATD) with clinically evident emphysema AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Anabolic Steroid PA – Danazol

Drug Name(s)

Danazol

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require BOTH of the following:

1. Patient has ONE of the following diagnoses:

A. Patient has an FDA labeled indication for the requested agent OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

A. Patient will NOT be using the requested agent in combination with another androgen or anabolic steroid OR

B. Prescriber has provided information in support of therapy with more than one agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Androgen Injectable PA - testosterone cypionate

Drug Name(s)

Depo-Testosterone

Testosterone Cypionate

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require ALL of the following:

1. Patient has ONE of the following diagnoses:

A. Patient's sex is male with AIDS/HIV-associated wasting syndrome AND BOTH of the following:

i. ONE of the following:

a. Unexplained involuntary weight loss (greater than 10% baseline body weight within 12 months, or 7.5% within 6 months) OR

b. Body mass index less than 20 kg/m² OR

c. At least 5% total body cell mass (BCM) loss within 6 months OR

d. BCM less than 35% of total body weight and BMI less than 27 kg/m² AND

ii. All other causes of weight loss have been ruled out OR

B. Patient's sex is female with metastatic/inoperable breast cancer OR

C. Patient's sex is male with primary or secondary (hypogonadotropic) hypogonadism OR

D. Patient's sex is male and is an adolescent with delayed puberty AND

2. If the patient's sex is a male, ONE of the following:

A. Patient is NOT currently receiving testosterone replacement therapy AND has ONE of the following pretreatment levels:

i. Total serum testosterone level that is below the testing laboratory's lower limit of the normal range or is less than 300 ng/dL OR

ii. Free serum testosterone level that is below the testing laboratory's lower limit of the normal range OR

B. Patient is currently receiving testosterone replacement therapy AND has ONE of the following current levels:

i. Total serum testosterone level that is within the testing laboratory's normal range OR below the testing laboratory's lower limit of the normal range OR is less than 300 ng/dL OR

ii. Free serum testosterone level is within the testing laboratory's normal range OR below the testing laboratory's normal range AND

3. ONE of the following:

A. Patient will NOT be using the requested agent in combination with another androgen or anabolic steroid OR

B. Prescriber has provided information in support of therapy with more than one agent

Age Restriction:**Prescriber Restrictions:**

Coverage Duration:

Approval will be 6 months for delayed puberty, 12 months for all other indications

Other Criteria:

Prior Authorization Group Description:

Androgen Injectable PA - testosterone enanthate

Drug Name(s)

Testosterone Enanthate

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require ALL of the following:

1. Patient has ONE of the following diagnoses:

A. Patient's sex is male with AIDS/HIV-associated wasting syndrome AND BOTH of the following:

i. ONE of the following:

- a. Unexplained involuntary weight loss (greater than 10% baseline body weight within 12 months, or 7.5% within 6 months) OR
- b. Body mass index less than 20 kg/m² OR
- c. At least 5% total body cell mass (BCM) loss within 6 months OR
- d. BCM less than 35% of total body weight and BMI less than 27 kg/m² AND

ii. All other causes of weight loss have been ruled out OR

B. Patient's sex is female with metastatic/inoperable breast cancer OR

C. Patient's sex is male with primary or secondary (hypogonadotropic) hypogonadism OR

D. Patient's sex is male and is an adolescent with delayed puberty AND

2. If the patient's sex is a male, ONE of the following:

A. Patient is NOT currently receiving testosterone replacement therapy AND has ONE of the following pretreatment levels:

- i. Total serum testosterone level that is below the testing laboratory's lower limit of the normal range or is less than 300 ng/dL OR
- ii. Free serum testosterone level that is below the testing laboratory's lower limit of the normal range OR

B. Patient is currently receiving testosterone replacement therapy AND has ONE of the following current levels:

- i. Total serum testosterone level that is within the testing laboratory's normal range OR below the testing laboratory's lower limit of the normal range OR is less than 300 ng/dL OR
- ii. Free serum testosterone level is within the testing laboratory's normal range OR below the testing laboratory's normal range AND

3. ONE of the following:

A. Patient will NOT be using the requested agent in combination with another androgen or anabolic steroid OR

B. Prescriber has provided information in support of therapy with more than one agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be 6 months for delayed puberty, 12 months for all other indications

Other Criteria:

Prior Authorization Group Description:

Androgen Topical PA

Drug Name(s)

Testosterone

Testosterone Pump

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require ALL of the following:

1. Patient has ONE of the following diagnoses:

A. Patient has AIDS/HIV-associated wasting syndrome AND BOTH of the following:

i. ONE of the following:

- a. Unexplained involuntary weight loss (greater than 10% baseline body weight within 12 months, or 5% within 6 months) OR
- b. Body mass index less than 20 kg/m² OR
- c. At least 5% total body cell mass (BCM) loss within 6 months OR
- d. In men: BCM less than 35% of total body weight and BMI less than 27 kg/m² OR
- e. In women: BCM less than 23% of total body weight and BMI less than 27 kg/m² AND

ii. All other causes of weight loss have been ruled out OR

B. Patient's sex is male with primary or secondary (hypogonadotropic) hypogonadism AND

2. If the patient's sex is male, ONE of the following:

A. Patient is NOT currently receiving testosterone replacement therapy AND has ONE of the following pretreatment levels:

- i. Total serum testosterone level that is below the testing laboratory's lower limit of the normal range or is less than 300 ng/dL OR
- ii. Free serum testosterone level that is below the testing laboratory's lower limit of the normal range OR

B. Patient is currently receiving testosterone replacement therapy AND has ONE of the following current levels:

- i. Total serum testosterone level that is within the testing laboratory's normal range OR below the testing laboratory's lower limit of the normal range OR is less than 300 ng/dL OR
- ii. Free serum testosterone level is within the testing laboratory's normal range OR below the testing laboratory's normal range AND

3. ONE of the following:

A. Patient will NOT be using the requested agent in combination with another androgen or anabolic steroid OR

B. Prescriber has submitted information in support of therapy with more than one agent

Age Restriction:

Prescriber Restrictions:

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Antipsychotics PA

Drug Name(s)

Aripiprazole
Aripiprazole Odt
Asenapine Maleate Sl
Bysanti
Chlorpromazine Hcl
Clozapine
Clozapine Odt
Fanapt
Fanapt Pack A
Fanapt Pack C
Fluphenazine Decanoate
Fluphenazine Hcl
Haloperidol
Haloperidol Decanoate
Haloperidol Lactate
Loxapine
Lurasidone Hcl
Lybalvi
Molindone Hcl
Olanzapine
Olanzapine Odt
Opipta
Paliperidone Er
Perphenazine
Pimozide
Quetiapine Fumarate
Quetiapine Fumarate Er
Rexulti
Risperidone
Risperidone Odt
Secuado
Thioridazine Hcl
Thiothixene
Trifluoperazine Hcl
Versacloz
Ziprasidone Mesylate

Indications:

All Medically-Accepted Indications.

Off-Label Uses:

Exclusion Criteria:

Required Medical Information:

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR

b. Prescriber states the patient is currently being treated with the requested agent OR

c. ONE of the following:

i. Patient has a diagnosis other than dementia-related psychosis or dementia-related behavioral symptoms OR

ii. Patient has dementia-related psychosis or dementia-related behavioral symptoms

AND BOTH of the following:

1. Dementia-related psychosis is determined to be severe or the associated behavior puts the patient or others in danger AND

2. Prescriber has discussed the risk of increased mortality with the patient and/or the patient's surrogate decision maker

Approval authorizations will apply to the requested medication only.

Age Restriction:

Prescriber Restrictions:

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Arcalyst PA

Drug Name(s)

Arcalyst

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. ONE of the following:

A. Patient has been diagnosed with Cryopyrin-Associated Periodic Syndromes (CAPS) including Familial Cold Auto-inflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS) OR

B. BOTH of the following:

i. Patient has a diagnosis of deficiency of interleukin-1 receptor antagonist AND

ii. The requested agent is being used for maintenance of remission OR

C. BOTH of the following:

i. Patient has a diagnosis of recurrent pericarditis AND

ii. The requested agent is being used to reduce the risk of recurrence AND

2. Patient will NOT be using the requested agent in combination with another biologic agent

Age Restriction:

For diagnosis of CAPS including FCAS or MWS, patient is 12 years of age or over.

For diagnosis of recurrent pericarditis and reduction in risk of recurrence, patient is 12 years of age or over.

Prescriber Restrictions:**Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Arikayce PA

Drug Name(s)

Arikayce

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Mycobacterium avium complex (MAC) lung disease AND
2. Patient has not achieved negative sputum cultures despite at least 6 consecutive months of treatment with standard combination antibiotic therapy for MAC lung disease [e.g., standard combination may include a macrolide (clarithromycin, azithromycin), a rifamycin (rifampin, rifabutin), and ethambutol] AND
3. Patient will continue treatment with a combination antibiotic therapy for MAC lung disease with the requested agent [e.g., combination may include a macrolide (clarithromycin, azithromycin), a rifamycin (rifampin, rifabutin), and ethambutol]

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Mycobacterium avium complex (MAC) lung disease AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will continue treatment with a combination antibiotic therapy for MAC lung disease with the requested agent [e.g., combination may include a macrolide (clarithromycin, azithromycin), a rifamycin (rifampin, rifabutin), and ethambutol]

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., infectious disease, immunologist, pulmonologist, thoracic specialist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Armodafinil PA

Drug Name(s)

Armodafinil

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another target agent (i.e., modafinil)

Age Restriction:

Patient is 17 years of age or over

Prescriber Restrictions:**Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Atopic Dermatitis PA – Eucrisa

Drug Name(s)

Eucrisa

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of atopic dermatitis AND
2. ONE of the following:
 - A. Patient has tried and had an inadequate response to a topical corticosteroid or topical corticosteroid combination preparation (e.g., hydrocortisone, triamcinolone) OR
 - B. Patient has an intolerance or hypersensitivity to a topical corticosteroid or topical corticosteroid combination preparation OR
 - C. Patient has an FDA labeled contraindication to a topical corticosteroid or topical corticosteroid combination preparation

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Atopic Dermatitis PA – Tacrolimus

Drug Name(s)

Tacrolimus

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ONE of the following:

1. Patient has a diagnosis of atopic dermatitis AND ONE of the following:
 - A. Patient has tried and had an inadequate response to a topical corticosteroid or topical corticosteroid combination preparation (e.g., hydrocortisone, triamcinolone) OR
 - B. Patient has an intolerance or hypersensitivity to a topical corticosteroid or topical corticosteroid combination preparation OR
 - C. Patient has an FDA labeled contraindication to a topical corticosteroid or topical corticosteroid combination preparation OR
2. Patient has an indication that is supported in CMS approved compendia for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Atovaquone PA

Drug Name(s)

Atovaquone

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

1. Patient has a diagnosis of mild-to-moderate *Pneumocystis jirovecii* pneumonia OR
2. Patient is using the requested agent for prevention of *Pneumocystis jirovecii* pneumonia AND

ii. ONE of the following:

1. Patient has an intolerance or hypersensitivity to trimethoprim/sulfamethoxazole (TMP/SMX) OR
2. Patient has an FDA labeled contraindication to trimethoprim/sulfamethoxazole (TMP/SMX) OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Attruby PA

Drug Name(s)

Attruby

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of cardiomyopathy of wild type or variant transthyretin-mediated amyloidosis (ATTR-CM) AND
2. The diagnosis has been confirmed by testing [e.g., stannous pyrophosphate (PYP) scanning, monoclonal antibody studies, biopsy, scintigraphy, genetic testing (TTR genotyping)] AND
3. The requested agent will be used to reduce cardiovascular death and cardiovascular-related hospitalization AND
4. Patient has New York Heart Association (NYHA) Functional Class I, II, or III heart failure AND
5. Patient has clinical manifestations of cardiomyopathy (e.g., dyspnea, fatigue, orthostatic hypotension, syncope, peripheral edema) AND
6. Patient will NOT be using the requested agent in combination with Amvuttra or a tafamidis agent for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of cardiomyopathy of wild type or variant transthyretin-mediated amyloidosis (ATTR-CM) AND
3. The requested agent will be used to reduce cardiovascular death and cardiovascular-related hospitalization AND
4. Patient has New York Heart Association (NYHA) Functional Class I, II, or III heart failure AND
5. Patient has had clinical benefit with the requested agent AND
6. Patient will NOT be using the requested agent in combination with Amvuttra or a tafamidis agent for the requested indication

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cardiologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Austedo PA

Drug Name(s)

Austedo

Austedo Xr

Austedo Xr Patient Titration Kit

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require ALL of the following:

1. ONE of the following:

A. Patient has a diagnosis of chorea associated with Huntington's disease AND BOTH of the following:

i. ONE of the following:

1. Patient does NOT have a current diagnosis of depression OR
2. Patient has a current diagnosis of depression and is being treated for depression AND

ii. ONE of the following:

1. Patient does NOT have a diagnosis of passive suicidal ideation and/or behavior OR
2. Patient has a diagnosis of passive suicidal ideation and/or behavior and must NOT be actively suicidal OR

B. Patient has a diagnosis of tardive dyskinesia AND ONE of the following:

- i. Prescriber has reduced the dose of or discontinued any medications known to cause tardive dyskinesia (i.e., dopamine receptor blocking agents) OR
- ii. Prescriber has provided clinical rationale indicating that a reduced dose or discontinuation of any medications known to cause tardive dyskinesia is not appropriate AND

2. Patient will NOT be using the requested agent in combination with a monoamine oxidase inhibitor (MAOI) AND

3. Patient will NOT be using the requested agent in combination with reserpine

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Benign Prostatic Hyperplasia PA – Tadalafil

Drug Name(s)

Tadalafil 2.5Mg, 5Mg

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

Requested agent will be used to treat erectile dysfunction ONLY AND FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of benign prostatic hyperplasia (BPH) AND
2. Patient has tried and had an insufficient response, intolerance or hypersensitivity, or FDA labeled contraindication to TWO alpha blocker agents (e.g., terazosin, doxazosin, tamsulosin)

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Benlysta SC PA

Drug Name(s)

Benlysta SC

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:
 - a. Patient has a diagnosis of active systemic lupus erythematosus (SLE) disease AND the following:
 - i. Patient will continue standard SLE therapy [corticosteroids (e.g., methylprednisolone, prednisone), hydroxychloroquine, immunosuppressives (e.g., azathioprine, methotrexate, oral cyclophosphamide)] in combination with the requested agent OR
 - b. Patient has a diagnosis of active lupus nephritis (LN) AND the following:
 - i. Patient will continue standard LN therapy [corticosteroids (e.g., methylprednisolone, prednisone), immunosuppressives (e.g., azathioprine, mycophenolate)] in combination with the requested agent AND
2. Patient will NOT be using the requested agent in combination with another biologic agent

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
 - a. Patient has diagnosis of active systemic lupus erythematosus (SLE) disease AND the following:
 - i. Patient will continue standard SLE therapy [corticosteroids (e.g., methylprednisolone, prednisone), hydroxychloroquine, immunosuppressives (e.g., azathioprine, methotrexate, oral cyclophosphamide)] in combination with the requested agent OR
 - b. Patient has a diagnosis of active lupus nephritis (LN) AND the following:
 - i. Patient will continue standard LN therapy [corticosteroids (e.g., methylprednisolone, prednisone), immunosuppressives (e.g., azathioprine, mycophenolate)] in combination with the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another biologic agent

Age Restriction:

For diagnosis of active systemic lupus erythematosus (SLE) disease, patient is 5 years of age or over. For diagnosis of active lupus nephritis (LN), patient is 5 years of age or over.

Prescriber Restrictions:**Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Benzodiazepines PA – Clobazam

Drug Name(s)

Clobazam

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
- b. Prescriber states the patient is currently being treated with the requested agent AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. BOTH of the following:

i. Patient has ONE of the following diagnoses:

- a. Seizure disorder OR
- b. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Benzodiazepines PA – Clorazepate

Drug Name(s)

Clorazepate Dipotassium

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
- b. Prescriber states the patient is currently being treated with the requested agent AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. BOTH of the following:

i. Patient has ONE of the following diagnoses:

- a. Seizure disorder OR
- b. Anxiety disorder AND ONE of the following:
 - 1) Patient has tried and has an inadequate response to a formulary selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) OR
 - 2) Patient has an intolerance or hypersensitivity to a formulary SSRI or SNRI OR
 - 3) Patient has an FDA labeled contraindication to a formulary SSRI or SNRI OR
- c. Alcohol withdrawal OR
- d. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Benzodiazepines PA – Diazepam

Drug Name(s)

Diazepam

Diazepam Intensol

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR

b. Prescriber states the patient is currently being treated with the requested agent AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. BOTH of the following:

i. Patient has ONE of the following diagnoses:

a. Seizure disorder OR

b. Anxiety disorder AND ONE of the following:

1) Patient has tried and had an inadequate response to a formulary selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) OR

2) Patient has an intolerance or hypersensitivity to a formulary SSRI or SNRI OR

3) Patient has an FDA labeled contraindication to a formulary SSRI or SNRI OR

c. Skeletal muscle spasms OR

d. Alcohol withdrawal OR

e. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Benzodiazepines PA – Lorazepam

Drug Name(s)

Lorazepam

Lorazepam Intensol

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR

b. Prescriber states the patient is currently being treated with the requested agent AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. BOTH of the following:

i. Patient has ONE of the following diagnoses:

a. Anxiety disorder AND ONE of the following:

1) Patient has tried and had an inadequate response to a formulary selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) OR

2) Patient has an intolerance or hypersensitivity to a formulary SSRI or SNRI OR

3) Patient has an FDA labeled contraindication to a formulary SSRI or SNRI OR

b. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Benzodiazepines PA – Sympazan

Drug Name(s)

Sympazan

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
- b. Prescriber states the patient is currently being treated with the requested agent AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. BOTH of the following:

i. Patient has ONE of the following diagnoses:

- a. Seizure disorder OR
- b. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Bexarotene Gel PA

Drug Name(s)

Bexarotene Gel

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent OR
 - C. ALL of the following:
 - i. ONE of the following:
 1. BOTH of the following:
 - a. Patient has a diagnosis of stage IA or IB cutaneous T-cell lymphoma (CTCL) with cutaneous lesions AND
 - b. ONE of the following:
 - i. Patient has refractory or persistent disease despite a previous treatment trial with a skin-directed therapy (e.g., topical corticosteroid, topical imiquimod) OR
 - ii. Patient has an intolerance or hypersensitivity to a previous treatment trial with a skin-directed therapy (e.g., topical corticosteroid, topical imiquimod) OR
 - iii. Patient has an FDA labeled contraindication to a previous treatment trial with a skin-directed therapy (e.g., topical corticosteroid, topical imiquimod) OR
 2. Patient has an indication that is supported in CMS approved compendia for the requested agent AND
 - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, oncologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND
 - iii. Patient does NOT have any FDA labeled contraindications to the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
3. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent OR
 - C. ALL of the following:
 - i. Patient has had clinical benefit with the requested agent AND
 - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, oncologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND
 - iii. Patient does NOT have any FDA labeled contraindications to the requested agent

Prior Authorization Group Description:

Biologic Immunomodulators PA – Actemra

Drug Name(s)

Actemra

Actemra Actpen

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
 - C. ONE of the following:
 - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
 - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
 - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
 - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
 - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Rinvoq solution, or Simlandi) is required for diagnosis of polyarticular juvenile idiopathic arthritis

Use of TWO preferred agents (Hadlima, Rinvoq tablets, or Simlandi) is required for diagnosis of rheumatoid arthritis

Use of ONE preferred agent (Rinvoq tablets) is required for diagnosis of giant cell arteritis

NO preferred agent is required for diagnoses of systemic sclerosis-associated interstitial lung disease (SSc-ILD), cytokine release syndrome, or systemic juvenile idiopathic arthritis

Prior Authorization Group Description:

Biologic Immunomodulators PA – Cosentyx

Drug Name(s)

Cosentyx

Cosentyx Sensoready Pen

Cosentyx Unoready

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
 - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
 - D. Patient's diagnosis does NOT require a conventional prerequisite agent OR
 - E. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
 - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
 - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Use of ONE conventional prerequisite agent is required for diagnosis of plaque psoriasis

NO prerequisites are required for diagnoses of ankylosing spondylitis, enthesitis related arthritis, hidradenitis suppurativa, non-radiographic axial spondyloarthritis, or psoriatic arthritis

Formulary conventional agents (topical or systemic) for plaque psoriasis include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

Prior Authorization Group Description:

Biologic Immunomodulators PA – Enbrel

Drug Name(s)

Enbrel

Enbrel Mini

Enbrel Sureclick

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
 - C. ONE of the following:
 - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
 - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
 - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
 - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
 - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Use of ONE preferred agent (Hadlima or Simlandi) is required for diagnoses of ankylosing spondylitis, psoriatic arthritis, adult plaque psoriasis, polyarticular juvenile idiopathic arthritis, or rheumatoid arthritis

NO preferred agent is required for diagnoses of juvenile psoriatic arthritis or pediatric plaque psoriasis

Prior Authorization Group Description:

Biologic Immunomodulators PA – Entyvio SC

Drug Name(s)

Entyvio Pen

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Biologic Immunomodulators PA – Hadlima

Drug Name(s)

Hadlima

Hadlima Pushtouch

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
 - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
 - D. Patient's diagnosis does NOT require a conventional prerequisite agent OR
 - E. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
 - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
 - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Use of ONE conventional prerequisite agent is required for diagnoses of plaque psoriasis, rheumatoid arthritis, or juvenile idiopathic arthritis

NO prerequisites are required for diagnoses of ankylosing spondylitis, moderate Crohn's disease, severe Crohn's disease, hidradenitis suppurativa, psoriatic arthritis, moderate ulcerative colitis, severe ulcerative colitis, or uveitis

Formulary conventional agents for rheumatoid arthritis or juvenile idiopathic arthritis include leflunomide, methotrexate, or sulfasalazine

Formulary conventional agents (topical or systemic) for plaque psoriasis include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

Prior Authorization Group Description:

Biologic Immunomodulators PA – Orencia

Drug Name(s)

Orencia

Orencia Clickject

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
 - C. ONE of the following:
 - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
 - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
 - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
 - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
 - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Rinvoq solution, or Simlandi) is required for diagnosis of juvenile idiopathic arthritis

Use of TWO preferred agents (Hadlima, Rinvoq tablets, or Simlandi) is required for diagnosis of rheumatoid arthritis

For patients 18 years of age or over, use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Pyzchiva, Rinvoq tablets, Rinvoq solution, Simlandi, Skyrizi, Steqeyma, Tremfya, or Ustekinumab-aekn) is required for diagnosis of psoriatic arthritis

For patients between 6 and less than 18 years of age, use of ONE preferred agent (Cosentyx, Otezla, Otezla XR, Pyzchiva, Steqeyma, Tremfya, or Ustekinumab-aekn) is required for diagnosis of psoriatic arthritis

For patients between 2 and less than 6 years of age, NO preferred agent is required for diagnosis of psoriatic arthritis

NO preferred agent is required for diagnosis of prophylaxis of acute graft vs host disease

Prior Authorization Group Description:

Biologic Immunomodulators PA – Pyzchiva

Drug Name(s)

Pyzchiva

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
 - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
 - D. Patient's diagnosis does NOT require a conventional prerequisite agent OR
 - E. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
 - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
 - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Use of ONE conventional prerequisite agent is required for diagnosis of plaque psoriasis

NO prerequisites are required for diagnoses of moderate Crohn's disease, severe Crohn's disease, psoriatic arthritis, moderate ulcerative colitis, or severe ulcerative colitis

Formulary conventional agents (topical or systemic) for plaque psoriasis include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

Prior Authorization Group Description:

Biologic Immunomodulators PA – Rinvoq Solution

Drug Name(s)

Rinvoq Lq

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
 - C. ONE of the following:
 - i. Patient's medication history indicates use of preferred TNF agent(s) OR
 - ii. Patient has an intolerance or hypersensitivity to preferred TNF agent(s) OR
 - iii. Patient has an FDA labeled contraindication to preferred TNF agent(s) OR
 - iv. The request is for an FDA labeled indication that is not covered by preferred TNF agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Use of ONE preferred TNF (Hadlima or Simlandi) is required for diagnoses of adult psoriatic arthritis or juvenile idiopathic arthritis

NO preferred TNF agent is required for diagnosis of pediatric psoriatic arthritis

Prior Authorization Group Description:

Biologic Immunomodulators PA – Rinvoq Tablet

Drug Name(s)

Rinvoq Tablet

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
 - C. ONE of the following:
 - i. BOTH of the following:
 - a. Patient has an FDA labeled indication other than moderate to severe atopic dermatitis for the requested agent AND
 - b. ONE of the following:
 1. Patient's medication history indicates use of preferred TNF agent(s) OR
 2. Patient has an intolerance or hypersensitivity to preferred TNF agent(s) OR
 3. Patient has an FDA labeled contraindication to preferred TNF agent(s) OR
 4. The request is for an FDA labeled indication that is not covered by preferred TNF agent(s) OR
 - ii. Patient has a diagnosis of moderate to severe atopic dermatitis AND ONE of the following:
 - a. Patient's medication history indicates use of TWO conventional prerequisite agents (i.e., ONE formulary topical corticosteroid AND ONE formulary topical calcineurin inhibitor) for the requested indication OR
 - b. Patient has an intolerance or hypersensitivity to TWO conventional prerequisite agents (i.e., ONE formulary topical corticosteroid AND ONE formulary topical calcineurin inhibitor) for the requested indication OR
 - c. Patient has an FDA labeled contraindication to TWO conventional prerequisite agents (i.e., ONE formulary topical corticosteroid AND ONE formulary topical calcineurin inhibitor) for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Age Restriction:

Prescriber Restrictions:**Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Use of ONE preferred TNF (Hadlima or Simlandi) is required for diagnoses of ankylosing spondylitis, rheumatoid arthritis, adult psoriatic arthritis, or juvenile idiopathic arthritis

Use of TWO conventional prerequisite agents are required for diagnosis of moderate to severe atopic dermatitis

NO preferred TNF agents are required for diagnoses of pediatric psoriatic arthritis, non-radiographic axial spondyloarthritis, giant cell arteritis, moderate Crohn's disease, severe Crohn's disease, moderate ulcerative colitis, or severe ulcerative colitis

Prior Authorization Group Description:

Biologic Immunomodulators PA – Selarsdi

Drug Name(s)

Ustekin-Aekn

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
 - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
 - D. Patient's diagnosis does NOT require a conventional prerequisite agent OR
 - E. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
 - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
 - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Use of ONE conventional prerequisite agent is required for diagnosis of plaque psoriasis

NO prerequisites are required for diagnoses of moderate Crohn's disease, severe Crohn's disease, psoriatic arthritis, moderate ulcerative colitis, or severe ulcerative colitis

Formulary conventional agents (topical or systemic) for plaque psoriasis include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

Prior Authorization Group Description:

Biologic Immunomodulators PA - Simlandi

Drug Name(s)

Simlandi

Indications:

All FDA-Approved Indications

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
 - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
 - D. Patient's diagnosis does NOT require a conventional prerequisite agent OR
 - E. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
 - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
 - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Use of ONE conventional prerequisite agent is required for diagnoses of plaque psoriasis, rheumatoid arthritis, or juvenile idiopathic arthritis

NO prerequisites are required for diagnoses of ankylosing spondylitis, moderate Crohn's disease, severe Crohn's disease, hidradenitis suppurativa, psoriatic arthritis, moderate ulcerative colitis, severe ulcerative colitis, or uveitis

Formulary conventional agents for rheumatoid arthritis or juvenile idiopathic arthritis include leflunomide, methotrexate, or sulfasalazine

Formulary conventional agents (topical or systemic) for plaque psoriasis include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

Prior Authorization Group Description:

Biologic Immunomodulators PA – Skyrizi

Drug Name(s)

Skyrizi

Skyrizi Pen

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
 - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
 - D. Patient's diagnosis does NOT require a conventional prerequisite agent OR
 - E. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
 - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
 - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Use of ONE conventional prerequisite agent is required for diagnosis of plaque psoriasis

NO prerequisites are required for diagnoses of moderate Crohn's disease, severe Crohn's disease, psoriatic arthritis, moderate ulcerative colitis, or severe ulcerative colitis

Formulary conventional agents (topical or systemic) for plaque psoriasis include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

Prior Authorization Group Description:

Biologic Immunomodulators PA – Steqeyma

Drug Name(s)

Steqeyma

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
 - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
 - D. Patient's diagnosis does NOT require a conventional prerequisite agent OR
 - E. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
 - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
 - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Use of ONE conventional prerequisite agent is required for diagnosis of plaque psoriasis

NO prerequisites are required for diagnoses of moderate Crohn's disease, severe Crohn's disease, psoriatic arthritis, moderate ulcerative colitis, or severe ulcerative colitis

Formulary conventional agents (topical or systemic) for plaque psoriasis include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

Prior Authorization Group Description:

Biologic Immunomodulators PA – Tremfya

Drug Name(s)

Tremfya

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
 - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
 - D. Patient's diagnosis does NOT require a conventional prerequisite agent OR
 - E. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
 - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
 - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Use of ONE conventional prerequisite agent is required for diagnosis of plaque psoriasis

NO prerequisites are required for diagnoses of moderate Crohn's disease, severe Crohn's disease, psoriatic arthritis, moderate ulcerative colitis, or severe ulcerative colitis

Formulary conventional agents (topical or systemic) for plaque psoriasis include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

Prior Authorization Group Description:

Biologic Immunomodulators PA - Tyenne

Drug Name(s)

Tyenne

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
 - C. ONE of the following:
 - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
 - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
 - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
 - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
 - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Rinvoq solution, or Simlandi) is required for diagnosis of polyarticular juvenile idiopathic arthritis

Use of TWO preferred agents (Hadlima, Rinvoq tablets, or Simlandi) is required for diagnosis of rheumatoid arthritis

Use of ONE preferred agent (Rinvoq tablets) is required for diagnosis of giant cell arteritis

NO preferred agent is required for diagnoses of cytokine release syndrome or systemic juvenile idiopathic arthritis

Prior Authorization Group Description:

Budesonide Oral ER PA – Entocort

Drug Name(s)

Budesonide Dr (Entocort)

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Budesonide Oral ER PA – Uceris

Drug Name(s)

Budesonide Er (Uceris)

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Carglumic PA

Drug Name(s)

Carglumic Acid

Indications:

All FDA-Approved Indications, Some Medically-Accepted Indications.

Off-Label Uses:

Acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA)

Exclusion Criteria:**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of ONE of the following:
 - a. Acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS) OR
 - b. Chronic hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS) OR
 - c. Acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA)AND
2. The requested dose is within FDA labeled dosing for the requested indication

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., geneticist, nephrologist, metabolic disorders) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Cayston PA

Drug Name(s)

Cayston

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. Documentation has been provided that indicates the patient has a *Pseudomonas aeruginosa* respiratory infection AND
3. ONE of the following:
 - a. Patient is NOT currently (within the past 60 days) being treated with another inhaled antibiotic (e.g., inhaled tobramycin) OR
 - b. Patient is currently (within the past 60 days) being treated with another inhaled antibiotic (e.g., inhaled tobramycin) AND ONE of the following:
 - i. Prescriber has confirmed that the other inhaled antibiotic will be discontinued, and that therapy will be continued only with the requested agent OR
 - ii. Prescriber has provided information in support of another inhaled antibiotic therapy used concurrently with or alternating with (i.e., continuous alternating therapy) the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Chenodal PA

Drug Name(s)

Chenodal

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of radiolucent stones in a well-opacifying gallbladder AND
2. The requested dose is within FDA labeled dosing for the requested indication

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Chorionic Gonadotropin PA

Drug Name(s)

Chorionic Gonadotropin

Pregnyl

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

Requested agent will be used to promote fertility AND requested agent will be used to treat erectile dysfunction ONLY AND FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of prepubertal cryptorchidism not due to anatomic obstruction OR

B. Patient's sex is male with a diagnosis of hypogonadotropic hypogonadism (hypogonadism secondary to pituitary deficiency) AND BOTH of the following:

i. Patient has a measured current or pretreatment total serum testosterone level that is below the testing laboratory's lower limit of the normal range or is less than 300 ng/dL OR a free serum testosterone level that is below the testing laboratory's lower limit of the normal range AND

ii. Patient has measured luteinizing hormone (LH) AND follicle-stimulating hormone (FSH) levels that are at (low-normal) or below the testing laboratory's normal range OR

C. Patient has an indication that is supported in CMS approved compendia for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Cinacalcet PA

Drug Name(s)

Cinacalcet Hcl

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has ONE of the following:

A. A diagnosis of hypercalcemia due to parathyroid carcinoma OR

B. A diagnosis of primary hyperparathyroidism (HPT) AND BOTH of the following:

i. Patient has a pretreatment serum calcium level that is above the testing laboratory's upper limit of normal AND

ii. Patient is unable to undergo parathyroidectomy OR

C. Another indication that is FDA approved or supported in CMS approved compendia for the requested agent not otherwise excluded from Part D [i.e., secondary hyperparathyroidism due to end-stage renal disease (ESRD) on dialysis]

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Cobenfy PA

Drug Name(s)

Cobenfy

Cobenfy Starter Pack

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent OR
 - C. ALL of the following:
 - i. Prescriber has assessed the patient's liver enzymes and bilirubin prior to starting therapy with the requested agent AND
 - ii. Prescriber has assessed the patient's heart rate prior to starting therapy with the requested agent AND
 - iii. ONE of the following:
 - a. Patient has tried and had an inadequate response to TWO antipsychotic agents (e.g., aripiprazole, haloperidol, loxapine, olanzapine, quetiapine, risperidone) for the requested indication OR
 - b. Patient has an intolerance or hypersensitivity to TWO antipsychotic agents (e.g., aripiprazole, haloperidol, loxapine, olanzapine, quetiapine, risperidone) OR
 - c. Patient has an FDA labeled contraindication to TWO antipsychotic agents (e.g., aripiprazole, haloperidol, loxapine, olanzapine, quetiapine, risperidone) AND
 - iv. Patient does NOT have any FDA labeled contraindications to the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent OR

C. ALL of the following:

- i. Prescriber has assessed the patient's liver enzymes and bilirubin as clinically indicated during treatment with the requested agent AND
- ii. Prescriber has assessed the patient's heart rate as clinically indicated during treatment with the requested agent AND
- iii. Patient does NOT have any FDA labeled contraindications to the requested agent AND
- iv. Patient has had clinical benefit with the requested agent

Prior Authorization Group Description:

Colony Stimulating Factors PA – Granix

Drug Name(s)

Granix

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, hematologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 6 months

Other Criteria:

Prior Authorization Group Description:

Corlanor PA

Drug Name(s)

Corlanor

Ivabradine Hcl

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require the following:

1. ONE of following:

A. ALL of the following:

- i. Patient has stable, symptomatic heart failure (e.g., NYHA Class II, III, IV: ACCF/AHA Class C, D) due to dilated cardiomyopathy (DCM) AND
- ii. The requested agent is for a pediatric patient, 6 months of age or over AND
- iii. Patient is in sinus rhythm with an elevated heart rate OR

B. ALL of the following:

- i. Patient has stable, symptomatic chronic heart failure (e.g., NYHA Class II, III, IV: ACCF/AHA Class C, D) AND
- ii. The requested agent is for an adult patient AND
- iii. Patient has a baseline OR current left ventricular ejection fraction of 35% or less AND
- iv. Patient is in sinus rhythm with a resting heart rate of 70 beats or greater per minute prior to initiating therapy with the requested agent AND

v. ONE of the following:

- a. Patient is on a maximally tolerated dose of beta blocker (e.g., bisoprolol, carvedilol, metoprolol) OR
- b. Patient has an intolerance, FDA labeled contraindications, or hypersensitivity to a beta blocker

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Cresemba PA

Drug Name(s)

Cresemba

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of invasive aspergillosis OR
- B. Patient has a diagnosis of invasive mucormycosis OR
- C. Patient has another indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require BOTH of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

- A. Patient has a diagnosis of invasive aspergillosis or invasive mucormycosis and patient has continued indicators of active disease (e.g., biomarkers in serum assay, microbiologic culture, radiographic evidence) OR
- B. BOTH of the following:
 - i. Patient has another indication that is supported in CMS approved compendia for the requested agent AND
 - ii. Patient has had clinical benefit with the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 6 months

Other Criteria:

Prior Authorization Group Description:

Crysvita PA

Drug Name(s)

Crysvita

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. BOTH of the following:

i. Patient has a diagnosis of X-linked hypophosphatemia (XLH) as confirmed by ONE of the following:

a. Genetic testing OR

b. Elevated levels of intact fibroblast growth factor 23 (FGF23) OR

c. Prescriber has provided information indicating the patient has a positive family history of XLH AND

ii. ONE of the following:

a. Patient's epiphyseal plate has not fused OR

b. Patient's epiphyseal plate has fused AND the patient is experiencing symptoms of XLH (e.g., bone pain, fractures, limited mobility) OR

B. Patient has a diagnosis of tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors AND BOTH of the following:

i. The requested agent is being used to treat FGF23 related hypophosphatemia AND

ii. The tumor cannot be curatively surgically resected or localized AND

2. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of X-linked hypophosphatemia (XLH) OR

B. Patient has a diagnosis of tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors AND

3. Patient has had clinical benefit with the requested agent (e.g., enhanced height velocity, improvement in lower extremity bowing and associated abnormalities, radiographic evidence of epiphyseal healing, improvement in bone pain, enhanced mobility, improvement in osteomalacia, improvement in fracture healing) AND

4. The requested dose is within FDA labeled dosing for the requested indication

Age Restriction:

Patient is within the FDA labeled age for the requested agent for the requested indication

Prescriber Restrictions:

Prescriber is a specialist in the area of the patient's diagnosis (e.g., nephrologist, endocrinologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Cystaran PA

Drug Name(s)

Cystaran

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., ophthalmologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Cystinosis Agents PA – Cystagon

Drug Name(s)

Cystagon

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of nephropathic cystinosis AND
2. Prescriber has performed a baseline white blood cell (WBC) cystine level test AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of nephropathic cystinosis AND
3. Patient has had clinical benefit with the requested agent (e.g., decrease in WBC cystine levels from baseline) AND
4. The requested dose is within FDA labeled dosing for the requested indication

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Dalfampridine PA

Drug Name(s)

Dalfampridine Er

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require the following:

1. Patient has a diagnosis of multiple sclerosis (MS)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of multiple sclerosis (MS) AND
3. Patient has had improvements or stabilization from baseline in timed walking speed (timed 25-foot walk)

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Droxidopa PA

Drug Name(s)

Droxidopa

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of neurogenic orthostatic hypotension (nOH) AND
2. Prescriber has performed baseline blood pressure readings while the patient is sitting or supine (lying face up), AND also within three minutes of standing from a supine position AND
3. Patient has a decrease of at least 20 mmHg in systolic blood pressure or 10 mmHg diastolic blood pressure within three minutes after standing AND
4. Patient has persistent and consistent symptoms of neurogenic orthostatic hypotension (nOH) caused by ONE of the following:
 - A. Primary autonomic failure [Parkinson's disease (PD), multiple system atrophy, or pure autonomic failure] OR
 - B. Dopamine beta-hydroxylase deficiency OR
 - C. Non-diabetic autonomic neuropathy AND
5. Prescriber has assessed the severity of the patient's baseline symptoms of dizziness, lightheadedness, feeling faint, or feeling like the patient may black out AND
6. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of neurogenic orthostatic hypotension (nOH) AND
3. Patient has had improvements or stabilization with the requested agent as indicated by improvement in severity from baseline symptoms of ONE of the following:
 - A. Dizziness
 - B. Lightheadedness
 - C. Feeling faint
 - D. Feeling like the patient may black out AND
4. The requested dose is within FDA labeled dosing for the requested indication

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cardiologist, neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be 1 month for initial, 3 months for renewal

Other Criteria:

Prior Authorization Group Description:

Dupixent PA

Drug Name(s)

Dupixent

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of:

- A. Patient (pt) has a diagnosis (dx) of allergic fungal rhinosinusitis (AFRS) AND the following:
 - i. Pt has a history of sino-nasal surgery (e.g., endoscopic sinus surgery) for the treatment of AFRS OR
- B. Pt has a dx of moderate-to-severe atopic dermatitis AND ALL of:
 - i. ONE of:
 - a. Pt has tried and failed a topical steroid (e.g., triamcinolone) OR
 - b. Pt has an intolerance, hypersensitivity, or an FDA labeled contraindication to a topical steroid AND
 - ii. For pts 2 years of age or over, ONE of:
 - a. Pt has tried and failed a topical calcineurin inhibitor (e.g., tacrolimus) OR
 - b. Pt has an intolerance, hypersensitivity, or an FDA labeled contraindication to a topical calcineurin inhibitor AND
 - iii. Pt will NOT be using the requested agent in combination with another biologic agent or a JAK inhibitor for the requested indication OR
- C. Pt has a dx of moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid dependent asthma AND BOTH of:
 - i. Pt is currently being treated with AND will continue asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, theophylline) in combination with the requested agent AND
 - ii. Pt will NOT be using the requested agent in combination with Xolair or with an injectable interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Fasenra, Nucala) for the requested indication OR
- D. Pt has a dx of bullous pemphigoid (BP) OR
- E. Pt has a dx of chronic rhinosinusitis with nasal polyposis (CRSwNP) AND the following:
 - i. BOTH of:
 - a. ONE of:
 - 1. Pt has tried and had an inadequate response to an oral systemic corticosteroid AND an intranasal corticosteroid (e.g., fluticasone) OR
 - 2. Pt has an intolerance, hypersensitivity, or an FDA labeled contraindication to an oral systemic corticosteroid AND an intranasal corticosteroid AND

Initial criteria continues: see Other Criteria

Age Restriction:

For dx of moderate-to-severe atopic dermatitis, pt is 6 months of age or over. For dx of moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid dependent asthma, pt is 6 years of age or over. For dx of CSU, pt is 2 years of age or over. For dx of CRSwNP, pt is 12 years of age or over. For dx of EoE, pt is 1 year of age or over. For dx of COPD with an eosinophilic phenotype, PN, or BP, pt is 18 years of age or over. For dx of AFRS, pt is 6 years of age or over.

Prescriber Restrictions:

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, dermatologist, immunologist, gastroenterologist, otolaryngologist, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

- b. Pt will continue standard maintenance therapy (e.g., intranasal corticosteroid) in combination with the requested agent OR
- F. Pt has a dx of eosinophilic esophagitis (EoE) confirmed by esophageal biopsy OR
- G. Pt has a dx of prurigo nodularis (PN) OR
- H. Pt has a dx of chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype AND BOTH of:
 - i. Pt is currently being treated with AND will continue COPD control therapy (e.g., ICS, LABA, LAMA) in combination with the requested agent AND
 - ii. Pt will NOT be using the requested agent in combination with Xolair or with an injectable interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Fasenra, Nucala) for the requested indication OR
- I. Pt has a dx of chronic spontaneous urticaria (CSU) AND BOTH of:
 - i. Pt has had over 6 weeks of hives and itching AND
 - ii. ONE of:
 - a. Pt has tried and had an inadequate response to a maximum tolerable H1 antihistamine therapy OR
 - b. Pt has an intolerance, hypersensitivity, or an FDA labeled contraindication to a maximum tolerable H1 antihistamine therapy

Criteria for renewal approval require ALL of:

1. Pt has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of:
 - A. Pt has a dx of allergic fungal rhinosinusitis (AFRS) OR
 - B. Pt has a dx of moderate-to-severe atopic dermatitis AND the following:
 - i. Pt will NOT be using the requested agent in combination with another biologic agent or a JAK inhibitor for the requested indication OR
 - C. Pt has a dx of moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid dependent asthma AND BOTH of:
 - i. Pt is currently being treated with AND will continue asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, theophylline) in combination with the requested agent AND

- ii. Pt will NOT be using the requested agent in combination with Xolair or with an injectable interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Fasenra, Nucala) for the requested indication OR
- D. Pt has a dx of bullous pemphigoid (BP) OR
- E. Pt has a dx of chronic rhinosinusitis with nasal polyposis (CRSwNP) AND the following:
 - i. Pt will continue standard maintenance therapy (e.g., intranasal corticosteroid) in combination with the requested agent OR
- F. Pt has a dx of eosinophilic esophagitis (EoE) OR
- G. Pt has a dx of prurigo nodularis (PN) OR
- H. Pt has a dx of chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype AND BOTH of:
 - i. Pt is currently being treated with AND will continue COPD control therapy (e.g., ICS, LABA, LAMA) in combination with the requested agent AND
 - ii. Pt will NOT be using the requested agent in combination with Xolair or with an injectable interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Fasenra, Nucala) for the requested indication OR
- I. Pt has a dx of chronic spontaneous urticaria (CSU) AND
- 3. Pt has had clinical benefit with the requested agent

Prior Authorization Group Description:

Emgality PA

Drug Name(s)

Emgality

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:
 - A. Patient has a diagnosis of migraine AND ALL of the following:
 - i. The requested agent is being used for migraine prophylaxis AND
 - ii. Patient has 4 or more migraine headache days per month AND
 - iii. Patient will NOT be using the requested agent in combination with another calcitonin gene-related peptide (CGRP) agent for migraine prophylaxis OR
 - B. Patient has a diagnosis of episodic cluster headache AND BOTH of the following:
 - i. Patient has had at least 5 cluster headache attacks AND
 - ii. Patient has had at least two cluster periods lasting 7 days to one year and separated by pain-free remission periods of 3 months or more

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
 - A. ALL of the following:
 - i. Patient has a diagnosis of migraine AND
 - ii. The requested agent is being used for migraine prophylaxis AND
 - iii. Patient will NOT be using the requested agent in combination with another calcitonin gene-related peptide (CGRP) agent for migraine prophylaxis OR
 - B. Patient has a diagnosis of episodic cluster headache AND
3. Patient has had clinical benefit with the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Emsam PA

Drug Name(s)

Emsam

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

- A. Patient has a diagnosis of major depressive disorder (MDD) OR
- B. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

- A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
- B. Prescriber states the patient is currently being treated with the requested agent OR
- C. BOTH of the following:
 - i. ONE of the following:
 - a. BOTH of the following:
 - i. Patient has a diagnosis of major depressive disorder (MDD) AND
 - ii. ONE of the following:
 - 1. Patient has tried and had an inadequate response to at least two different oral antidepressants (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), mirtazapine, bupropion) OR
 - 2. Patient has an intolerance or hypersensitivity to at least two different oral antidepressants (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), mirtazapine, bupropion) OR
 - 3. Patient has an FDA labeled contraindication to at least two different oral antidepressants (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), mirtazapine, bupropion) OR
 - b. Patient has an indication that is supported in CMS approved compendia for the requested agent AND
 - ii. Patient does NOT have any FDA labeled contraindications to the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
 - A. Patient has a diagnosis of major depressive disorder (MDD) OR
 - B. Patient has an indication that is supported in CMS approved compendia for the requested agent AND
3. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent OR
 - C. BOTH of the following:
 - i. Patient has had clinical benefit with the requested agent AND
 - ii. Patient does NOT have any FDA labeled contraindications to the requested agent

Prior Authorization Group Description:

Epidiolex PA

Drug Name(s)

Epidiolex

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of seizures associated with ONE of the following:

A. Lennox-Gastaut syndrome OR

B. Dravet syndrome OR

C. Tuberous sclerosis complex AND

2. The requested dose is within FDA labeled dosing for the requested indication

Age Restriction:

Patient is within the FDA labeled age for the requested agent

Prescriber Restrictions:**Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Erythropoietin Stimulating Agents PA - Epogen/Procrit

Drug Name(s)

Procrit

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require BOTH of the following:

1. The requested agent is being prescribed for ONE of the following:

A. To reduce the possibility of allogeneic blood transfusion in a surgery patient AND the patient's hemoglobin level is greater than 10 g/dL but less than or equal to 13 g/dL OR

B. Anemia due to myelosuppressive chemotherapy for a non-myeloid malignancy AND ALL of the following:

i. Patient's hemoglobin level is less than 10 g/dL for patients initiating ESA therapy OR less than 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) AND

ii. Patient is being concurrently treated with chemotherapy with or without radiation (there must be a minimum of 2 additional months of planned chemotherapy) AND

iii. The intent of chemotherapy is non-curative OR

C. Anemia associated with chronic kidney disease in a patient NOT on dialysis AND ALL of the following:

i. Patient's hemoglobin level is less than 10 g/dL for patients initiating ESA therapy OR 11 g/dL or less for patients stabilized on therapy (measured within the previous 4 weeks) AND

ii. The rate of hemoglobin decline indicates the likelihood of requiring a RBC transfusion AND

iii. The intent of therapy is to reduce the risk of alloimmunization and/or other RBC transfusion related risks OR

D. Anemia due to myelodysplastic syndrome AND the patient's hemoglobin level is less than 12 g/dL for patients initiating ESA therapy OR less than or equal to 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) OR

E. Anemia resulting from zidovudine treatment of HIV infection AND the patient's hemoglobin level is less than 12 g/dL for patients initiating ESA therapy OR less than or equal to 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) OR

Initial criteria continues: see Other Criteria

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

1 month for surgery (reduce transfusion possibility), 6 months for chemo, 12 months for other

Other Criteria:

F. Another indication that is supported in CMS approved compendia for the requested agent AND the patient's hemoglobin level is less than 12 g/dL for patients initiating ESA therapy OR less than or equal to 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) AND

2. Patient's transferrin saturation and serum ferritin have been evaluated

Drug is also subject to Part B versus Part D review.

Prior Authorization Group Description:

Erythropoietin Stimulating Agents PA – Retacrit

Drug Name(s)

Retacrit

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require BOTH of the following:

1. The requested agent is being prescribed for ONE of the following:

A. To reduce the possibility of allogeneic blood transfusion in a surgery patient AND the patient's hemoglobin level is greater than 10 g/dL but less than or equal to 13 g/dL OR

B. Anemia due to myelosuppressive chemotherapy for a non-myeloid malignancy AND ALL of the following:

i. Patient's hemoglobin level is less than 10 g/dL for patients initiating ESA therapy OR less than 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) AND

ii. Patient is being concurrently treated with chemotherapy with or without radiation (there must be a minimum of 2 additional months of planned chemotherapy) AND

iii. The intent of chemotherapy is non-curative OR

C. Anemia associated with chronic kidney disease in a patient NOT on dialysis AND ALL of the following:

i. Patient's hemoglobin level is less than 10 g/dL for patients initiating ESA therapy OR 11 g/dL or less for patients stabilized on therapy (measured within the previous 4 weeks) AND

ii. The rate of hemoglobin decline indicates the likelihood of requiring a RBC transfusion AND

iii. The intent of therapy is to reduce the risk of alloimmunization and/or other RBC transfusion related risks OR

D. Anemia resulting from zidovudine treatment of HIV infection AND the patient's hemoglobin level is less than 12 g/dL for patients initiating ESA therapy OR less than or equal to 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) OR

E. Another indication that is supported in CMS approved compendia for the requested agent AND the patient's hemoglobin level is less than 12 g/dL for patients initiating ESA therapy OR less than or equal to 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) AND

2. Patient's transferrin saturation and serum ferritin have been evaluated

Drug is also subject to Part B versus Part D review.

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

1 month for surgery (reduce transfusion possibility), 6 months for chemo, 12 months for other
Other Criteria:

Prior Authorization Group Description:

Fentanyl Oral PA - Fentanyl lozenge

Drug Name(s)

Fentanyl Citrate Oral Transmucosal

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. ONE of the following:

a. Patient has a documented diagnosis (i.e., medical records) of chronic cancer pain due to an active malignancy AND BOTH of the following:

i. Prescriber has provided the patient's type of cancer AND

ii. There is evidence of a claim that the patient is currently being treated with a long-acting opioid with the requested agent within the past 90 days OR

b. Patient has a diagnosis that is supported in CMS approved compendia for the requested agent AND

2. Patient will NOT be using the requested agent in combination with any other oral fentanyl agent

Age Restriction:

Patient is 16 years of age or over

Prescriber Restrictions:**Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Fintepla PA

Drug Name(s)

Fintepla

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of seizures associated with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS) AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent OR
 - C. ALL of the following:
 - i. An echocardiogram assessment will be obtained before and during treatment with the requested agent, to evaluate for valvular heart disease and pulmonary arterial hypertension AND
 - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND
 - iii. Patient does NOT have any FDA labeled contraindications to the requested agent

Age Restriction:

Patient is within the FDA labeled age for the requested agent

Prescriber Restrictions:**Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Flucytosine PA

Drug Name(s)

Flucytosine

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require ALL of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
 - A. The requested agent will be used in combination with amphotericin B OR
 - B. Prescriber has provided information in support of therapy without concurrent amphotericin B for the requested indication AND
3. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 10 weeks

Other Criteria:

Prior Authorization Group Description:

Focalin PA

Drug Name(s)

Dexmethylphenidate Hcl (Focalin)

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Gammagard/Gammaked/Gamunex-C PA

Drug Name(s)

Gammagard Liquid Erc

Gammagard Liquid

Gamunex-C

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ONE of the following:

1. Patient has ONE of the following diagnoses:

- A. Primary immunodeficiency [e.g., congenital agammaglobulinemia, common variable immunodeficiency (CVID), severe combined immunodeficiency, Wiskott-Aldrich Syndrome, X-linked agammaglobulinemia (XLA), humoral immunodeficiency, IgG subclass deficiency with or without IgA deficiency] OR
- B. B-cell chronic lymphocytic leukemia OR multiple myeloma AND ONE of the following:
 - i. Patient has a history of infections OR
 - ii. Patient has evidence of specific antibody deficiency OR
 - iii. Patient has hypogammaglobulinemia OR
- C. Idiopathic thrombocytopenia purpura AND ONE of the following:
 - i. Patient has failed ONE conventional therapy [e.g., corticosteroids (e.g., methylprednisolone), or immunosuppressants (e.g., mycophenolate)] OR
 - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR
- D. Dermatomyositis AND ONE of the following:
 - i. Patient has failed ONE conventional therapy [e.g., corticosteroids (e.g., methylprednisolone) or immunosuppressants (e.g., azathioprine)] OR
 - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR
- E. Polymyositis AND ONE of the following:
 - i. Patient has failed ONE conventional therapy [e.g., corticosteroids (e.g., methylprednisolone) or immunosuppressants (e.g., azathioprine)] OR
 - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR
- F. Severe rheumatoid arthritis AND ONE of the following:
 - i. Patient has failed ONE conventional therapy [e.g., tumor necrosis factor antagonists (e.g., Enbrel), DMARDS (e.g., methotrexate)] OR
 - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR

Criteria continues: see Other Criteria

Age Restriction:

Prescriber Restrictions:**Coverage Duration:**

Approval will be for 6 months for indications in Other Criteria, 12 months for all others

Other Criteria:

- G. Myasthenia gravis (MG) AND ONE of the following:
 - i. Patient is in acute myasthenic crisis OR
 - ii. Patient has severe refractory MG (e.g., major functional disability/weakness) AND ONE of the following:
 - a) Patient has failed ONE immunomodulator therapy (i.e., corticosteroid, pyridostigmine, or azathioprine) OR
 - b) Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE immunomodulator therapy OR
- H. Multiple sclerosis (MS) AND BOTH of the following:
 - i. Patient has a diagnosis of relapsing remitting MS (RRMS) AND
 - ii. Patient has had an insufficient response, documented failure, or FDA labeled contraindication to TWO MS agents (e.g., Avonex, Betaseron, dimethyl fumarate, fingolimod, glatiramer, Glatopa, Kesimpta, Plegridy, Vumerity) OR
- I. Acquired von Willebrand hemophilia AND ONE of the following:
 - i. Patient has failed ONE conventional therapy (e.g., desmopressin, von Willebrand factor replacement therapy, corticosteroids, FEIBA, or recombinant factor VIIa) OR
 - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR
- J. Refractory pemphigus vulgaris AND ONE of the following:
 - i. Patient has failed ONE conventional immunosuppressive therapy (e.g., azathioprine, cyclophosphamide, mycophenolate, corticosteroids) OR
 - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional immunosuppressive therapy OR
- 2. ONE of the following:
 - A. Patient has another FDA labeled indication for the requested agent OR
 - B. Patient has an indication that is supported in CMS approved compendia for the requested agent

Indications with 6 months approval duration: Acquired von Willebrand hemophilia, Guillain-Barre Syndrome, Lambert-Eaton myasthenia syndrome, Kawasaki disease, CMV induced pneumonitis in solid organ transplant, Toxic shock syndrome due to invasive group A streptococcus, Toxic epidermal necrolysis and Stevens-Johnson syndrome

Drug is also subject to Part B versus Part D review.

Prior Authorization Group Description:

Gaucher Enzyme Replacement PA – Cerezyme

Drug Name(s)

Cerezyme

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Gaucher disease type 1 (GD1) or type 3 (GD3) confirmed by ONE of the following:
 - A. A baseline (prior to therapy for the requested indication) glucocerebrosidase enzyme activity of less than or equal to 15% of mean normal in peripheral blood leukocytes, fibroblasts, or other nucleated cells OR
 - B. Confirmation of genetic mutation of glucocerebrosidase (GBA) gene with two disease-causing alleles AND
2. Prior to any treatment for the intended diagnosis, the patient has had at least ONE of the following clinical presentations:
 - A. Anemia [defined as mean hemoglobin (Hb) level below the testing laboratory's lower limit of the normal range based on age and gender] OR
 - B. Thrombocytopenia (defined as a platelet count of less than 100,000 per microliter) OR
 - C. Hepatomegaly OR
 - D. Splenomegaly OR
 - E. Growth failure (i.e., growth velocity below the standard mean for age) OR
 - F. Evidence of bone disease with other causes ruled out AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Gaucher disease type 1 (GD1) or type 3 (GD3) AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, geneticist, hematologist, hepatologist, specialist in metabolic diseases) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Gaucher Enzyme Replacement PA – Elelyso

Drug Name(s)

Elelyso

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Gaucher disease type 1 (GD1) confirmed by ONE of the following:
 - A. A baseline (prior to therapy for the requested indication) glucocerebrosidase enzyme activity of less than or equal to 15% of mean normal in peripheral blood leukocytes, fibroblasts, or other nucleated cells OR
 - B. Confirmation of genetic mutation of glucocerebrosidase (GBA) gene with two disease-causing alleles AND
2. Prior to any treatment for the intended diagnosis, the patient has had at least ONE of the following clinical presentations:
 - A. Anemia [defined as mean hemoglobin (Hb) level below the testing laboratory's lower limit of the normal range based on age and gender] OR
 - B. Thrombocytopenia (defined as a platelet count of less than 100,000 per microliter) OR
 - C. Hepatomegaly OR
 - D. Splenomegaly OR
 - E. Growth failure (i.e., growth velocity below the standard mean for age) OR
 - F. Evidence of bone disease with other causes ruled out AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Gaucher disease type 1 (GD1) AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, geneticist, hematologist, hepatologist, specialist in metabolic diseases) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Gaucher Enzyme Replacement PA – Vpriv

Drug Name(s)

Vpriv

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Gaucher disease type 1 (GD1) confirmed by ONE of the following:
 - A. A baseline (prior to therapy for the requested indication) glucocerebrosidase enzyme activity of less than or equal to 15% of mean normal in peripheral blood leukocytes, fibroblasts, or other nucleated cells OR
 - B. Confirmation of genetic mutation of glucocerebrosidase (GBA) gene with two disease-causing alleles AND
2. Prior to any treatment for the intended diagnosis, the patient has had at least ONE of the following clinical presentations:
 - A. Anemia [defined as mean hemoglobin (Hb) level below the testing laboratory's lower limit of the normal range based on age and gender] OR
 - B. Thrombocytopenia (defined as a platelet count of less than 100,000 per microliter) OR
 - C. Hepatomegaly OR
 - D. Splenomegaly OR
 - E. Growth failure (i.e., growth velocity below the standard mean for age) OR
 - F. Evidence of bone disease with other causes ruled out AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Gaucher disease type 1 (GD1) AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, geneticist, hematologist, hepatologist, specialist in metabolic diseases) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Gauze Pads PA

Drug Name(s)

Gauze Pads

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

This program will be implemented as a dynamic PA.

Criteria for approval require BOTH of the following:

1. The requested medical supply product will be used in the delivery of insulin to the body AND
2. Patient's medication history includes use of insulin within the past 180 days

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Growth Hormone PA – Omnitrope

Drug Name(s)

Omnitrope

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

For Children – Criteria for initial approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of Turner Syndrome OR
- B. Patient has a diagnosis of Prader-Willi Syndrome OR
- C. Patient has a diagnosis of panhypopituitarism AND BOTH of the following:
 - i. Deficiencies in 3 or more pituitary axes AND
 - ii. Measured serum IGF-1 (insulin-like growth factor-1) levels are below the age and sex-appropriate reference range when off GH therapy OR
- D. Patient has a diagnosis of growth hormone deficiency (GHD) or short stature AND BOTH of the following:
 - i. Patient has ONE of the following:
 - a. Height more than 2 standard deviations (SD) below the mean for age and sex OR
 - b. Height more than 1.5 SD below the midparental height OR
 - c. A decrease in height SD of more than 0.5 over one year in children at least 2 years of age OR
 - d. Height velocity more than 2 SD below the mean over one year or more than 1.5 SD sustained over two years AND
 - ii. Failure of at least 2 growth hormone (GH) stimulation tests (e.g., peak GH value of less than 10 mcg/L after stimulation, or otherwise considered abnormal as determined by testing lab) OR
- E. Patient has a diagnosis of small for gestational age (SGA) AND ALL of the following:
 - i. Patient is at least 2 years of age AND
 - ii. Documented birth weight and/or length that is 2 or more SD below the mean for gestational age AND
 - iii. At 24 months of age, the patient fails to manifest catch-up growth evidenced by a height that remains 2 or more SD below the mean for age and sex

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

For Children – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the preferred agent through the plan's Prior Authorization criteria AND
2. Patient has been diagnosed with ONE of the following:
 - A. Growth Hormone Deficiency, Short Stature OR
 - B. Panhypopituitarism OR
 - C. Prader-Willi Syndrome OR
 - D. Small for Gestational Age (SGA) OR
 - E. Turner Syndrome AND
3. ALL of the following:
 - A. Patient does NOT have closed epiphyses AND
 - B. Patient is being monitored for adverse effects of therapy with the requested agent AND
 - C. Patient's height has increased or height velocity has improved since initiation or last approval of the requested agent

For Adults – Criteria for initial approval require the following:

1. Patient has been diagnosed with ONE of the following:
 - A. Childhood growth hormone deficiency (GHD) with genetic or organic origin AND ONE of the following:
 - i. Low IGF-1 (insulin-like growth factor-1) level without GH replacement therapy OR
 - ii. Failure of at least one growth hormone (GH) stimulation test as an adult (e.g., peak GH value of 5 mcg/L or lower after stimulation, or otherwise considered abnormal as determined by testing lab) OR
 - B. Acquired adult GHD secondary to structural lesions or trauma AND ONE of the following:
 - i. Patient has a diagnosis of panhypopituitarism AND BOTH of the following:
 - a. Deficiencies in 3 or more pituitary axes AND
 - b. Low IGF-1 level without GH replacement therapy OR
 - ii. Patient has failed at least one growth hormone (GH) stimulation test as an adult OR
 - C. Idiopathic GHD (adult or childhood onset) AND the patient has failed at least two growth hormone (GH) stimulation tests as an adult

For Adults – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the preferred agent through the plan's Prior Authorization criteria AND
2. Patient has been diagnosed with ONE of the following:
 - A. Childhood growth hormone deficiency (GHD) with genetic or organic origin OR
 - B. Acquired adult GHD secondary to structural lesions or trauma OR
 - C. Idiopathic GHD (adult or childhood onset) AND
3. Patient is being monitored for adverse effects of therapy with the requested agent AND
4. Patient's IGF-1 level has been evaluated to confirm the appropriateness of the current dose AND
5. Patient has had clinical benefit with the requested agent (i.e., body composition, hip-to-waist ratio, cardiovascular health, bone mineral density, serum cholesterol, physical strength, or quality of life)

Prior Authorization Group Description:

HAE PA – Haegarda

Drug Name(s)

Haegarda

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of hereditary angioedema (HAE) which has been confirmed via two confirmatory tests of C1-INH antigenic level, C1-INH functional level, and C4 level as follows:
 - a. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type I)]: decreased quantities of C4 and C1-INH (antigenic and functional level) OR
 - b. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type II)]: decreased quantities of C4 and C1-INH function (C1-INH protein level may be normal) OR
 - c. Hereditary angioedema (HAE) with normal C1INH [HAE-nI-C1INH (Type III)]: Normal levels of C4 and C1-INH [antigenic and functional level (at baseline and during an attack)] AND ONE of the following:
 - i. BOTH of the following:
 1. Family history of angioedema AND
 2. ALL other causes of angioedema have been ruled out OR
 - ii. Patient demonstrates a Factor XII mutation, angiopoietin-1 (ANGPT1) mutation, plasminogen (PLG) mutation, kininogen1 mutation, heparan sulfate 3-O-sulfotransferase 6 gene mutation, or myoferlin gene mutation that is associated with the disease AND
2. Medications known to cause angioedema (e.g., ACE-Inhibitors, estrogens, angiotensin II receptor blockers) have been evaluated and discontinued when appropriate AND
3. The requested agent will be used for prophylaxis against HAE attacks AND
4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for prophylaxis against HAE attacks

Age Restriction:

Patient is within the FDA labeled age for the requested agent

Prescriber Restrictions:**Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hereditary angioedema (HAE) AND
3. The requested agent is being used for prophylaxis against HAE attacks AND
4. Patient has had a decrease in the frequency or severity of acute attacks or has had stabilization of disease from use of the requested agent AND

5. Patient will NOT be using the requested agent in combination with another HAE agent indicated for prophylaxis against HAE attacks

Prior Authorization Group Description:

HAE PA – Icatibant

Drug Name(s)

Icatibant Acetate

Sajazir

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of hereditary angioedema (HAE) which has been confirmed via two confirmatory tests of C1-INH antigenic level, C1-INH functional level, and C4 level as follows:
 - a. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type I)]: decreased quantities of C4 and C1-INH (antigenic and functional level) OR
 - b. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type II)]: decreased quantities of C4 and C1-INH function (C1-INH protein level may be normal) OR
 - c. Hereditary angioedema (HAE) with normal C1INH [HAE-nI-C1INH (Type III)]: Normal levels of C4 and C1-INH [antigenic and functional level (at baseline and during an attack)] AND ONE of the following:
 - i. BOTH of the following:
 1. Family history of angioedema AND
 2. ALL other causes of angioedema have been ruled out OR
 - ii. Patient demonstrates a Factor XII mutation, angiopoietin-1 (ANGPT1) mutation, plasminogen (PLG) mutation, kininogen1 mutation, heparan sulfate 3-O-sulfotransferase 6 gene mutation, or myoferlin gene mutation that is associated with the disease AND
2. Medications known to cause angioedema (e.g., ACE-Inhibitors, estrogens, angiotensin II receptor blockers) have been evaluated and discontinued when appropriate AND
3. The requested agent will be used to treat acute HAE attacks AND
4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for treatment of acute HAE attacks

Age Restriction:

Patient is within the FDA labeled age for the requested agent

Prescriber Restrictions:**Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hereditary angioedema (HAE) AND
3. The requested agent will be used to treat acute HAE attacks AND

4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for treatment of acute HAE attacks AND
5. Patient has had a decrease in the frequency or severity of acute attacks or stabilization of disease from use of the requested agent

Prior Authorization Group Description:

High Risk Medication PA - All Starts

Drug Name(s)

Cyproheptadine Hcl

Dicyclomine Hcl

Diphenoxylate/Atropine

Hydroxyzine Hcl

Scopolamine

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require ALL of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested high-risk medication AND
2. Prescriber has indicated that the benefits of the requested high-risk medication outweigh the risks for the patient AND
3. Prescriber has indicated that the risks and potential side effects of the requested high-risk medication have been discussed with the patient

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Imiquimod PA

Drug Name(s)

Imiquimod Cream 5%

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has ONE of the following diagnoses:

- A. Actinic keratosis OR
- B. Superficial basal cell carcinoma OR
- C. External genital and/or perianal warts/condyloma acuminata OR
- D. Squamous cell carcinoma OR
- E. Basal cell carcinoma OR
- F. Another indication that is supported in CMS approved compendia for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

4 months for Actinic keratosis, other diagnoses - see Other Criteria

Other Criteria:

2 months for Superficial basal cell carcinoma, Squamous cell carcinoma, or Basal cell carcinoma

4 months for External genital and/or perianal warts/condyloma acuminata

12 months for All other diagnoses

Prior Authorization Group Description:

Inbrija PA

Drug Name(s)

Inbrija

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require BOTH of the following:

1. The requested agent will be used for intermittent treatment of OFF episodes in patients with Parkinson's disease AND
2. The requested agent will be used in combination with carbidopa/levodopa

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Ingrezza PA

Drug Name(s)

Ingrezza

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of chorea associated with Huntington's disease AND BOTH of the following:

i. ONE of the following:

1. Patient does NOT have a current diagnosis of depression OR
2. Patient has a current diagnosis of depression and is being treated for depression AND

ii. ONE of the following:

1. Patient does NOT have a diagnosis of passive suicidal ideation and/or behavior OR
2. Patient has a diagnosis of passive suicidal ideation and/or behavior and must NOT be actively suicidal OR

B. Patient has a diagnosis of tardive dyskinesia AND ONE of the following:

i. Prescriber has reduced the dose of or discontinued any medications known to cause tardive dyskinesia (i.e., dopamine receptor blocking agents) OR

ii. Prescriber has provided clinical rationale indicating that a reduced dose or discontinuation of any medications known to cause tardive dyskinesia is not appropriate

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Injectable Oncology PA

Drug Name(s)

Firmagon

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR

B. Prescriber states the patient is currently being treated with the requested agent OR

C. ALL of the following:

i. Genetic testing has been completed, if required, for therapy with the requested agent and results indicate the requested agent is appropriate AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent AND

iii. Patient does NOT have any FDA labeled limitations of use that is not otherwise supported in NCCN guidelines

May also be subject to Part B versus Part D review.

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Insulin Pen Needle PA

Drug Name(s)

Insulin Pen Needle

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

This program will be implemented as a dynamic PA.

Criteria for approval require BOTH of the following:

1. The requested medical supply product will be used in the delivery of insulin to the body AND
2. Patient's medication history includes use of insulin within the past 180 days

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Insulin Syringe_Needle PA

Drug Name(s)

Insulin Syringe/Needle

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

This program will be implemented as a dynamic PA.

Criteria for approval require BOTH of the following:

1. The requested medical supply product will be used in the delivery of insulin to the body AND
2. Patient's medication history includes use of insulin within the past 180 days

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Iron Chelating Agents PA – Exjade

Drug Name(s)

Deferasirox (Exjade)

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. Patient has a diagnosis of chronic iron overload due to a non-transfusion dependent thalassemia syndrome AND ONE of the following:

- i. A liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight OR
- ii. A serum ferritin greater than 300 mcg/L OR
- iii. MRI confirmation of iron deposition OR

B. Patient has a diagnosis of chronic iron overload due to blood transfusions AND

2. Patient will NOT be using the requested agent in combination with another iron chelating agent (e.g., deferiprone) for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of chronic iron overload due to a non-transfusion dependent thalassemia syndrome OR

B. Patient has a diagnosis of chronic iron overload due to blood transfusions AND

3. Patient has had clinical benefit with the requested agent AND

4. Patient will NOT be using the requested agent in combination with another iron chelating agent (e.g., deferiprone) for the requested indication

Age Restriction:

Patient is within the FDA labeled age for the requested agent for the requested indication

Prescriber Restrictions:**Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Iron Chelating Agents PA – Jadenu

Drug Name(s)

Deferasirox (Jadenu)

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. Patient has a diagnosis of chronic iron overload due to a non-transfusion dependent thalassemia syndrome AND ONE of the following:

- i. A liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight OR
- ii. A serum ferritin greater than 300 mcg/L OR
- iii. MRI confirmation of iron deposition OR

B. Patient has a diagnosis of chronic iron overload due to blood transfusions AND

2. Patient will NOT be using the requested agent in combination with another iron chelating agent (e.g., deferiprone) for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of chronic iron overload due to a non-transfusion dependent thalassemia syndrome OR

B. Patient has a diagnosis of chronic iron overload due to blood transfusions AND

3. Patient has had clinical benefit with the requested agent AND

4. Patient will NOT be using the requested agent in combination with another iron chelating agent (e.g., deferiprone) for the requested indication

Age Restriction:

Patient is within the FDA labeled age for the requested agent for the requested indication

Prescriber Restrictions:**Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Isotretinoin PA

Drug Name(s)

Accutane

Amnesteem

Claravis

Isotretinoin

Zenatane

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
3. Patient has had clinical benefit with the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

Other Criteria:

Prior Authorization Group Description:

Ivermectin Tablet PA

Drug Name(s)

Ivermectin Tablet

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 4 months

Other Criteria:

Prior Authorization Group Description:

Jubbonti PA

Drug Name(s)

Jubbonti

Indications:

All FDA-Approved Indications, Some Medically-Accepted Indications.

Off-Label Uses:

Osteopenia (osteoporosis prophylaxis)

Exclusion Criteria:

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require ALL of:

1. ONE of:

A. Patient's (pt) sex is male or the pt is postmenopausal with a diagnosis of osteoporosis AND BOTH of:

i. Pt's diagnosis was confirmed by ONE of:

1. A fragility fracture in the hip or spine OR
2. A T-score of -2.5 or lower OR
3. A T-score of -1.0 to -2.5 AND ONE of:
 - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
 - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
 - c. A FRAX 10-year probability of hip fracture of 3% or greater AND

ii. ONE of:

1. Pt is at a very high fracture risk as defined by ONE of:
 - a. Pt had a recent fracture (within the past 12 months) OR
 - b. Pt had fractures while on FDA approved osteoporosis therapy OR
 - c. Pt has had multiple fractures OR
 - d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
 - e. Pt has a very low T-score (less than -3.0) OR
 - f. Pt is at high risk for falls or has a history of injurious falls OR
 - g. Pt has a very high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%) or by other validated fracture risk algorithm OR
2. ONE of:
 - a. Pt's medication history includes use of a bisphosphonate OR
 - b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR

B. Pt is requesting the agent for osteopenia (osteoporosis prophylaxis) AND ALL of:

i. ONE of:

1. Pt's sex is male and the pt is 50 years of age or over OR
2. Pt is postmenopausal AND

- ii. Pt has a T-score between -1.0 to -2.50 AND
- iii. ONE of:
 - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
 - b. 10-year probability of a hip fracture 3% and greater per FRAX OR
 - c. 10-year probability of a major OP-related fracture 20% and greater per FRAX AND
- iv. ONE of:
 - a. Pt's medication history includes use of a bisphosphonate OR

Criteria continues: See Other Criteria

Age Restriction:

Prescriber Restrictions:

Coverage Duration:

Approval will be for 12 months

Other Criteria:

- b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- C. Pt's sex is a female with a diagnosis of breast cancer who is receiving aromatase inhibitor therapy AND ONE of:
 - i. Pt's medication history includes use of a bisphosphonate OR
 - ii. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- D. Pt's sex is male with a diagnosis of prostate cancer receiving androgen deprivation therapy (ADT) AND ONE of:
 - i. Pt's medication history includes use of a bisphosphonate OR
 - ii. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- E. Pt has a diagnosis of glucocorticoid-induced osteoporosis AND ALL of:
 - i. Pt is either initiating or continuing systemic glucocorticoids in a daily dose equivalent to 7.5 mg or greater of prednisone AND
 - ii. Pt is expected to remain on glucocorticoids for at least 6 months AND
 - iii. Pt's diagnosis was confirmed by ONE of:
 - 1. A fragility fracture in the hip or spine OR
 - 2. A T-score of -2.5 or lower OR
 - 3. A T-score of -1.0 to -2.5 AND ONE of:
 - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
 - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
 - c. A FRAX 10-year probability of hip fracture of 3% or greater AND
 - iv. ONE of:
 - 1. Pt is at high fracture risk as defined by ONE of:
 - a. Pt had a recent fracture (within the past 12 months) OR
 - b. Pt had fractures while on FDA approved osteoporosis therapy OR

- c. Pt has had multiple fractures OR
- d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
- e. Pt has a very low T-score (less than -2.5) OR
- f. Pt is at high risk for falls or has a history of injurious falls OR
- g. Pt has a high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 20%, hip fracture greater than 3%) or by other validated fracture risk algorithm OR

2. ONE of:

- a. Pt's medication history includes use of a bisphosphonate OR
- b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate AND

2. ONE of:

- A. Pt has a pretreatment or current calcium level that is NOT below the lower limit of the testing laboratory's normal range OR
- B. Pt has a pretreatment or current calcium level that is below the lower limit of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
- C. Prescriber has indicated that the pt is not at risk for hypocalcemia (not including risk associated with the requested agent) AND

3. Pt will NOT be using the requested agent in combination with a bisphosphonate, another form of denosumab, romosozumab-aqcg, or parathyroid hormone analog (e.g., abaloparatide, teriparatide) for the requested indication AND

4. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

Prior Authorization Group Description:

Jynarque PA

Drug Name(s)

Tolvaptan (Jynarque)

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of autosomal dominant polycystic kidney disease (ADPKD) confirmed by ONE of the following:

A. Ultrasound OR

B. MRI or CT scan OR

C. Genetic testing AND

2. Patient is at risk of rapid disease progression AND

3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. Patient has a diagnosis of autosomal dominant polycystic kidney disease (ADPKD) AND

3. Patient has had clinical benefit with the requested agent AND

4. The requested dose is within FDA labeled dosing for the requested indication

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., nephrologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Kalydeco PA

Drug Name(s)

Kalydeco

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. ONE of the following:
 - A. Patient has ONE of the CFTR gene mutations or a mutation in the CFTR gene that is responsive based on in vitro data, as indicated in the FDA label, confirmed by genetic testing OR
 - B. Patient has another CFTR gene mutation(s) that is responsive to the requested agent, as indicated in the FDA label, confirmed by genetic testing AND
3. Patient is NOT homozygous for the F508del mutation AND
4. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of cystic fibrosis AND
3. Patient has had improvement or stabilization with the requested agent [e.g., improvement in FEV1 from baseline, increase in weight/BMI, improvement from baseline Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain score, improvements in respiratory symptoms (cough, sputum production, and difficulty breathing), and/or reduced number of pulmonary exacerbations] AND
4. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

Age Restriction:

Patient is within the FDA labeled age for the requested agent

Prescriber Restrictions:

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cystic fibrosis, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Kerendia PA

Drug Name(s)

Kerendia

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Leuprolide PA

Drug Name(s)

Eligard

Leuprolide Acetate

Lupron Depot

Lupron Depot-Ped

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent OR
 - C. BOTH of the following:
 - i. Patient is NOT currently being treated with the requested agent AND
 - ii. Patient does NOT have any FDA labeled contraindications to the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

L-glutamine PA

Drug Name(s)

L-glutamine

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of sickle cell disease AND
2. Patient is using the requested agent to reduce the acute complications of sickle cell disease AND
3. ONE of the following:
 - A. Patient has tried and had an inadequate response to maximally tolerated dose of hydroxyurea OR
 - B. Patient has an intolerance or hypersensitivity to hydroxyurea OR
 - C. Patient has an FDA labeled contraindication to hydroxyurea

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of sickle cell disease AND
3. Patient is using the requested agent to reduce the acute complications of sickle cell disease AND
4. Patient has had clinical benefit with the requested agent

Age Restriction:

Patient is within the FDA labeled age for the requested agent

Prescriber Restrictions:**Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Lidocaine Topical PA - Lidocaine Patch

Drug Name(s)

Lidocaine Patch

Lidocan

Tridacaine Patch

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has ONE of the following diagnoses:

- A. Pain associated with postherpetic neuralgia (PHN) OR
 - B. Pain associated with diabetic neuropathy OR
 - C. Neuropathic pain associated with cancer, or cancer treatment OR
 - D. Another diagnosis that is supported in CMS approved compendia for the requested agent
- AND

2. ONE of the following:

- A. Patient has tried and had an inadequate response to a conventional therapy [e.g., gabapentin, pregabalin, oral prescription NSAID (non-steroidal anti-inflammatory drug)] for the requested indication OR
- B. Patient has an intolerance or hypersensitivity to a conventional therapy OR
- C. Patient has an FDA labeled contraindication to a conventional therapy

Prescriber Restrictions:**Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Lidocaine Topical PA - Lidocaine/prilocaine Cream

Drug Name(s)

Lidocaine/Prilocaine

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. The requested agent will be used for ONE of the following:
 - A. Local analgesia on normal intact skin OR
 - B. Topical anesthetic for dermal procedures OR
 - C. Adjunctive anesthesia prior to local anesthetic infiltration in adult male genital skin OR
 - D. Anesthesia for minor procedures on female external genitalia OR
 - E. Another indication that is supported in CMS approved compendia for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Linezolid PA

Drug Name(s)

Linezolid

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND ONE of the following:

- a. The requested agent is prescribed by an infectious disease specialist or the prescriber has consulted with an infectious disease specialist on treatment of this patient OR
- b. Patient has a documented infection due to vancomycin-resistant *Enterococcus faecium* OR
- c. Patient has a diagnosis of pneumonia caused by *Staphylococcus aureus* or *Streptococcus pneumoniae* AND ONE of the following:
 - i. Patient has a documented infection that is resistant to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole, OR that is resistant to vancomycin OR
 - ii. Patient has an intolerance or hypersensitivity to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole OR
 - iii. Patient has an FDA labeled contraindication to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole OR
 - iv. Patient has an intolerance or hypersensitivity to vancomycin OR
 - v. Patient has an FDA labeled contraindication to vancomycin OR
- d. Patient has a documented skin and skin structure infection, including diabetic foot infections, caused by *Staphylococcus aureus*, *Streptococcus pyogenes*, or *Streptococcus agalactiae* AND ONE of the following:
 - i. Patient has a documented infection that is resistant to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole, OR that is resistant to vancomycin at the site of infection OR
 - ii. Patient has an intolerance or hypersensitivity to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole OR
 - iii. Patient has an FDA labeled contraindication to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole OR

Criteria continues: see Other Criteria

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 3 months

Other Criteria:

- iv. Patient has an intolerance or hypersensitivity to vancomycin OR

- v. Patient has an FDA labeled contraindication to vancomycin AND
- 2. Patient will NOT be using the requested agent in combination with Sivextro (tedizolid) for the same infection AND
- 3. The requested dose is within FDA labeled dosing for the requested indication

Prior Authorization Group Description:

Mavyret PA

Drug Name(s)

Mavyret

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require ALL of the following:

1. ONE of the following:

A. Patient has a diagnosis of hepatitis C confirmed by serological markers OR

B. Patient is a hepatitis C virus (HCV) - uninfected solid organ transplant recipient AND BOTH of the following:

i. Patient received an HCV - viremic donor organ AND

ii. The requested agent is being used for prophylaxis AND

2. Prescriber has screened the patient for current or prior hepatitis B viral (HBV) infection and if positive, will monitor the patient for HBV flare-up or reactivation during and after treatment with the requested agent AND

3. The requested agent will be used in a treatment regimen and length of therapy that is supported in FDA approved labeling or AASLD/IDSA guidelines for the patient's diagnosis and genotype AND

4. The requested dose is within FDA labeled dosing or supported in AASLD/IDSA guideline dosing for the requested indication

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist or infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Duration of therapy: Based on FDA approved labeling or AASLD/IDSA guideline supported

Other Criteria:

Prior Authorization Group Description:

Memantine PA

Drug Name(s)

Memantine Hcl Titration Pak

Memantine Hcl

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

PA does NOT apply to patients greater than or equal to 30 years of age

Criteria for approval require the following:

1. Patient is younger than 30 years of age AND ONE of the following:
 - A. Patient has a diagnosis of moderate to severe dementia of the Alzheimer's type OR
 - B. Patient has an indication that is supported in CMS approved compendia for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Methylin PA

Drug Name(s)

Methylphenidate Hcl (Methylin)

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Methylphenidate ER Tablet PA

Drug Name(s)

Methylphenidate Hcl Er Tablet

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Miebo PA

Drug Name(s)

Miebo

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Mifepristone PA

Drug Name(s)

Mifepristone

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Cushing's syndrome AND
2. ONE of the following:
 - A. Patient has type 2 diabetes mellitus OR
 - B. Patient has glucose intolerance as defined by a 2-hour glucose tolerance test plasma glucose value of 140-199 mg/dL AND
3. ONE of the following:
 - A. Patient had an inadequate response to surgical resection OR
 - B. Patient is NOT a candidate for surgical resection

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Cushing's syndrome AND
3. Patient has had clinical benefit with the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Migranal PA

Drug Name(s)

Dihydroergotamine Mesylate Spray

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. The requested agent will be used for the treatment of acute migraine with or without aura AND
2. ONE of the following:
 - A. Patient has tried and had an inadequate response to TWO triptan agents with differing active ingredients (e.g., sumatriptan, rizatriptan) OR
 - B. Patient has an intolerance or hypersensitivity to a triptan agent OR
 - C. Patient has an FDA labeled contraindication to a triptan agent AND
3. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., triptan, 5HT-1F, acute CGRP)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. The requested agent will be used for the treatment of acute migraine with or without aura AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., triptan, 5HT-1F, acute CGRP)

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Modafinil PA

Drug Name(s)

Modafinil

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another target agent (i.e., armodafinil)

Age Restriction:

Patient is 17 years of age or over

Prescriber Restrictions:**Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Mounjaro PA

Drug Name(s)

Mounjaro

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

Requested agent will be used for weight loss alone

Required Medical Information:

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent within the past 180 days OR
 - C. ALL of the following:
 - i. Patient does NOT have any FDA labeled contraindications to the requested agent AND
 - ii. Patient will NOT be using the requested agent in combination with another GLP-1 agonist agent, or an agent containing a GLP-1 agonist AND
 - iii. Patient will NOT be using the requested agent in combination with an agent containing a dipeptidyl peptidase-4 (DPP-4) inhibitor

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

MS PA – Avonex

Drug Name(s)

Avonex

Avonex Pen

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

MS PA – Betaseron

Drug Name(s)

Betaseron

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

MS PA - Dimethyl Fumarate

Drug Name(s)

Dimethyl Fumarate

Dimethyl Fumarate Starterpack

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

MS PA – Fingolimod

Drug Name(s)

Fingolimod Hcl

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication AND
3. Prescriber will perform an electrocardiogram prior to initiating treatment

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

MS PA – Glatiramer

Drug Name(s)

Glatiramer Acetate

Glatopa

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

MS PA – Kesimpta

Drug Name(s)

Kesimpta

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

MS PA – Plegridy

Drug Name(s)

Plegridy

Plegridy Starter Pack

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

MS PA – Vumerity

Drug Name(s)

Vumerity

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Nexletol PA

Drug Name(s)

Nexletol

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. Patient has a diagnosis of heterozygous familial hypercholesterolemia (HeFH) AND ONE of the following:

- i. Genetic confirmation of one mutant allele at the LDLR, Apo-B, PCSK9, or 1/LDLRAP1 gene OR
- ii. Pretreatment LDL-C greater than 190 mg/dL (greater than 4.9 mmol/L) OR
- iii. Patient has clinical manifestations of HeFH (e.g., cutaneous xanthomas, tendon xanthomas, corneal arcus, tuberous xanthoma, or xanthelasma) OR
- iv. Patient has “definite” or “possible” familial hypercholesterolemia as defined by the Simon Broome criteria OR
- v. Patient has a Dutch Lipid Clinic Network criteria score of greater than 5 OR

B. Patient is at increased risk of major adverse cardiovascular events (MACE) [coronary heart disease death, myocardial infarction (MI), stroke, coronary revascularization] AND the requested agent will be used to reduce the risk of these events OR

C. Patient has a diagnosis of hypercholesterolemia [not associated with HeFH or increased risk of MACE] AND

2. ONE of the following:

- A. Patient is on statin therapy OR
- B. Patient has an intolerance to TWO different statins OR
- C. Patient has an FDA labeled contraindication to a statin

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan’s Prior Authorization criteria AND

2. ONE of the following:

- A. Patient has a diagnosis of heterozygous familial hypercholesterolemia (HeFH) OR
- B. Patient is at increased risk of major adverse cardiovascular events (MACE) [coronary heart disease death, myocardial infarction (MI), stroke, coronary revascularization] AND the requested agent will be used to reduce the risk of these events OR

- C. Patient has a diagnosis of hypercholesterolemia [not associated with HeFH or increased risk of MACE] AND
- 3. ONE of the following:
 - A. Patient is on statin therapy OR
 - B. Patient has an intolerance to TWO different statins OR
 - C. Patient has an FDA labeled contraindication to a statin AND
- 4. Patient has had clinical benefit with the requested agent

Prior Authorization Group Description:

Nexlizet PA

Drug Name(s)

Nexlizet

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. Patient has a diagnosis of heterozygous familial hypercholesterolemia (HeFH) AND ONE of the following:

i. Genetic confirmation of one mutant allele at the LDLR, Apo-B, PCSK9, or 1/LDLRAP1 gene OR

ii. Pretreatment LDL-C greater than 190 mg/dL (greater than 4.9 mmol/L) OR

iii. Patient has clinical manifestations of HeFH (e.g., cutaneous xanthomas, tendon xanthomas, corneal arcus, tuberous xanthoma, or xanthelasma) OR

iv. Patient has “definite” or “possible” familial hypercholesterolemia as defined by the Simon Broome criteria OR

v. Patient has a Dutch Lipid Clinic Network criteria score of greater than 5 OR

B. Patient is at increased risk of major adverse cardiovascular events (MACE) [coronary heart disease death, myocardial infarction (MI), stroke, coronary revascularization] AND the requested agent will be used to reduce the risk of these events OR

C. Patient has a diagnosis of hypercholesterolemia [not associated with HeFH or increased risk of MACE] AND

2. ONE of the following:

A. Patient is on statin therapy OR

B. Patient has an intolerance to TWO different statins OR

C. Patient has an FDA labeled contraindication to a statin

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan’s Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of heterozygous familial hypercholesterolemia (HeFH) OR

B. Patient is at increased risk of major adverse cardiovascular events (MACE) [coronary heart disease death, myocardial infarction (MI), stroke, coronary revascularization] AND the requested agent will be used to reduce the risk of these events OR

- C. Patient has a diagnosis of hypercholesterolemia [not associated with HeFH or increased risk of MACE] AND
- 3. ONE of the following:
 - A. Patient is on statin therapy OR
 - B. Patient has an intolerance to TWO different statins OR
 - C. Patient has an FDA labeled contraindication to a statin AND
- 4. Patient has had clinical benefit with the requested agent

Prior Authorization Group Description:

Nuedexta PA

Drug Name(s)

Nuedexta

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of pseudobulbar affect OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Nuplazid PA

Drug Name(s)

Nuplazid

Indications:

All FDA-Approved Indications.

Off-Label Uses:

Exclusion Criteria:

Required Medical Information:

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

Age Restriction:

Prescriber Restrictions:

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Nurtec PA

Drug Name(s)

Nurtec

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of migraine AND
2. ONE of the following:
 - A. The requested agent is being used for the treatment of acute migraine with or without aura AND BOTH of the following:
 - i. ONE of the following:
 - a. Patient has tried and had an inadequate response to a triptan (e.g., sumatriptan, rizatriptan) agent OR
 - b. Patient has an intolerance, or hypersensitivity to a triptan OR
 - c. Patient has an FDA labeled contraindication to a triptan AND
 - ii. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., 5HT-1F, ergotamine, acute CGRP) OR
 - B. The requested agent is being used for migraine prophylaxis AND BOTH of the following:
 - i. Patient has 4 or more migraine headache days per month AND
 - ii. Patient will NOT be using the requested agent in combination with another calcitonin gene-related peptide (CGRP) agent for migraine prophylaxis

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of migraine AND
3. ONE of the following:
 - A. The requested agent is being used for the treatment of acute migraine with or without aura AND BOTH of the following:
 - i. Patient has had clinical benefit with the requested agent AND
 - ii. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., 5HT-1F, ergotamine, acute CGRP) OR
 - B. The requested agent is being used for migraine prophylaxis AND BOTH of the following:
 - i. Patient has had clinical benefit with the requested agent AND
 - ii. Patient will NOT be using the requested agent in combination with another calcitonin gene-related peptide (CGRP) agent for migraine prophylaxis

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Ofev PA

Drug Name(s)

Nintedanib

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:
 - A. BOTH of the following:
 - i. Patient has a diagnosis of idiopathic pulmonary fibrosis (IPF) AND
 - ii. Patient has no known explanation for interstitial lung disease (ILD) or pulmonary fibrosis (e.g., radiation, drugs, metal dusts, sarcoidosis, or any connective tissue disease known to cause ILD) OR
 - B. BOTH of the following:
 - i. Patient has a diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) AND
 - ii. Patient's diagnosis has been confirmed on high-resolution computed tomography (HRCT) or chest radiography scans OR
 - C. BOTH of the following:
 - i. Patient has a diagnosis of chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype AND
 - ii. Patient's diagnosis has been confirmed on high-resolution computed tomography (HRCT)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of ONE of the following:
 - A. Idiopathic pulmonary fibrosis (IPF) OR
 - B. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) OR
 - C. Chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype AND
3. Patient has had clinical benefit with the requested agent

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., pathologist, pulmonologist, radiologist, rheumatologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Omnipod PA

Drug Name(s)

Omnipod Kit

Omnipod Pods

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of diabetes mellitus AND
2. Patient is on an insulin regimen of 3 or more injections per day AND
3. ONE of the following:
 - A. Patient is testing glucose levels 4 or more times per day OR
 - B. Patient is using a continuous glucose monitor (CGM)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of diabetes mellitus AND
3. Patient has had clinical benefit with the requested agent (e.g., stable or improved glycemic control)

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Ophthalmic Immunomodulators PA – Xiidra

Drug Name(s)

Xiidra

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Opioids ER PA - Fentanyl Patch

Drug Name(s)

Fentanyl Patch

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of cancer-related pain OR
- B. Patient has a diagnosis of pain due to sickle cell disease OR
- C. Patient is undergoing treatment of chronic non-cancer pain AND ONE of the following:
 - i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - ii. Prescriber states the patient is currently being treated with the requested agent within the past 90 days OR
 - iii. ALL of the following:
 - a. Prescriber has completed a formal, consultative evaluation including BOTH of the following:
 - 1. Diagnosis AND
 - 2. A medical history which includes previous and current pharmacological and non-pharmacological therapy for the requested diagnosis AND
 - b. The requested agent is NOT prescribed as an as-needed (prn) analgesic AND
 - c. Prescriber has confirmed that a patient-specific pain management plan is on file for the patient AND
 - d. ONE of the following:
 - 1. Patient's medication history includes use of an immediate-acting opioid OR
 - 2. Patient has an intolerance or hypersensitivity to an immediate-acting opioid OR
 - 3. Patient has an FDA labeled contraindication to an immediate-acting opioid AND
 - e. Prescriber has reviewed the patient's records in the state's prescription drug monitoring program (PDMP) AND has determined that the opioid dosages and combinations of opioids and other controlled substances within the patient's records do NOT indicate the patient is at high risk for overdose AND
 - f. Patient does NOT have any FDA labeled contraindications to the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Opioids ER PA – Morphine

Drug Name(s)

Morphine Sulfate Er

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of cancer-related pain OR
- B. Patient has a diagnosis of pain due to sickle cell disease OR
- C. Patient is undergoing treatment of chronic non-cancer pain AND ONE of the following:
 - i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - ii. Prescriber states the patient is currently being treated with the requested agent within the past 90 days OR
 - iii. ALL of the following:
 - a. Prescriber has completed a formal, consultative evaluation including BOTH of the following:
 - 1. Diagnosis AND
 - 2. A medical history which includes previous and current pharmacological and non-pharmacological therapy for the requested diagnosis AND
 - b. The requested agent is NOT prescribed as an as-needed (prn) analgesic AND
 - c. Prescriber has confirmed that a patient-specific pain management plan is on file for the patient AND
 - d. ONE of the following:
 - 1. Patient's medication history includes use of an immediate-acting opioid OR
 - 2. Patient has an intolerance or hypersensitivity to an immediate-acting opioid OR
 - 3. Patient has an FDA labeled contraindication to an immediate-acting opioid AND
 - e. Prescriber has reviewed the patient's records in the state's prescription drug monitoring program (PDMP) AND has determined that the opioid dosages and combinations of opioids and other controlled substances within the patient's records do NOT indicate the patient is at high risk for overdose AND
 - f. Patient does NOT have any FDA labeled contraindications to the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months
Other Criteria:

Prior Authorization Group Description:

Opioids ER PA – Tramadol

Drug Name(s)

Tramadol Hcl Er

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of cancer-related pain OR
- B. Patient has a diagnosis of pain due to sickle cell disease OR
- C. Patient is undergoing treatment of chronic non-cancer pain AND ONE of the following:
 - i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - ii. Prescriber states the patient is currently being treated with the requested agent within the past 90 days OR
 - iii. ALL of the following:
 - a. Prescriber has completed a formal, consultative evaluation including BOTH of the following:
 - 1. Diagnosis AND
 - 2. A medical history which includes previous and current pharmacological and non-pharmacological therapy for the requested diagnosis AND
 - b. The requested agent is NOT prescribed as an as-needed (prn) analgesic AND
 - c. Prescriber has confirmed that a patient-specific pain management plan is on file for the patient AND
 - d. ONE of the following:
 - 1. Patient's medication history includes use of an immediate-acting opioid OR
 - 2. Patient has an intolerance or hypersensitivity to an immediate-acting opioid OR
 - 3. Patient has an FDA labeled contraindication to an immediate-acting opioid AND
 - e. Prescriber has reviewed the patient's records in the state's prescription drug monitoring program (PDMP) AND has determined that the opioid dosages and combinations of opioids and other controlled substances within the patient's records do NOT indicate the patient is at high risk for overdose AND
 - f. Patient does NOT have any FDA labeled contraindications to the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months
Other Criteria:

Prior Authorization Group Description:

Orkambi PA

Drug Name(s)

Orkambi

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. ONE of the following:
 - A. Patient has the presence of the F508del mutation on both alleles (homozygous) of the CFTR gene confirmed by genetic testing OR
 - B. Patient has another CFTR gene mutation(s) that is responsive to the requested agent, as indicated in the FDA label, confirmed by genetic testing AND
3. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of cystic fibrosis AND
3. Patient has had improvement or stabilization with the requested agent [e.g., improvement in FEV1 from baseline, increase in weight/BMI, improvement from baseline Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain score, improvements in respiratory symptoms (cough, sputum production, and difficulty breathing), and/or reduced number of pulmonary exacerbations] AND
4. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

Age Restriction:

Patient is within the FDA labeled age for the requested agent

Prescriber Restrictions:

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cystic fibrosis, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Osenvelt PA

Drug Name(s)

Osenvelt

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require ALL of the following:

1. ONE of the following:

A. Patient has a diagnosis of multiple myeloma AND BOTH of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. ONE of the following:

1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR

2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR

3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR

B. Patient has a diagnosis of prostate cancer AND ALL of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. Patient has bone metastases AND

iii. ONE of the following:

1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR

2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR

3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR

Criteria continues: see Other Criteria

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

C. Patient has a solid tumor cancer diagnosis (e.g., thyroid, non-small cell lung, kidney cancer, or breast cancer) AND ALL of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. Patient has bone metastases AND

- iii. ONE of the following:
 - 1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
 - 2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
 - 3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR
- D. Patient has a diagnosis of giant cell tumor of bone AND ONE of the following:
 - i. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
 - ii. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
 - iii. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR
- E. Patient has a diagnosis of hypercalcemia of malignancy AND
- 2. Patient will NOT be using the requested agent in combination with another form of denosumab AND
- 3. The requested dose is within FDA labeled dosing for the requested indication

Prior Authorization Group Description:

Otezla PA

Drug Name(s)

Otezla

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:
 - A. BOTH of the following:
 - i. Patient has a diagnosis of plaque psoriasis AND
 - ii. ONE of the following:
 1. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 2. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
 3. Patient's medication history indicates use of a biologic immunomodulator agent for the same FDA labeled indication OR
 4. Patient has tried and had an inadequate response to at least ONE conventional prerequisite agent for the requested indication OR
 5. Patient has an intolerance or hypersensitivity to at least ONE conventional prerequisite agent for the requested indication OR
 6. Patient has an FDA labeled contraindication to at least ONE conventional prerequisite agent for the requested indication OR
 - B. Patient has a diagnosis of active psoriatic arthritis OR
 - C. Patient has a diagnosis of oral ulcers associated with Behcet's disease (BD)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has ONE of the following diagnoses:
 - A. Plaque psoriasis OR
 - B. Active psoriatic arthritis OR
 - C. Oral ulcers associated with Behcet's disease (BD) AND
3. Patient has had clinical benefit with the requested agent (slowing of disease progression or decrease in symptom severity and/or frequency)

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Formulary conventional agent required for diagnosis of plaque psoriasis

Formulary conventional agents for plaque psoriasis include cyclosporine, methotrexate, tazarotene, topical calcitriol, or topical corticosteroids

NO prerequisites are required for diagnoses of active psoriatic arthritis or oral ulcers associated with Behcet's disease (BD)

Prior Authorization Group Description:

Otezla Xr PA

Drug Name(s)

Otezla Xr

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:
 - A. BOTH of the following:
 - i. Patient has a diagnosis of plaque psoriasis AND
 - ii. ONE of the following:
 1. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 2. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
 3. Patient's medication history indicates use of a biologic immunomodulator agent for the same FDA labeled indication OR
 4. Patient has tried and had an inadequate response to at least ONE conventional prerequisite agent for the requested indication OR
 5. Patient has an intolerance or hypersensitivity to at least ONE conventional prerequisite agent for the requested indication OR
 6. Patient has an FDA labeled contraindication to at least ONE conventional prerequisite agent for the requested indication OR
 - B. Patient has a diagnosis of active psoriatic arthritis OR
 - C. Patient has a diagnosis of oral ulcers associated with Behcet's disease (BD)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has ONE of the following diagnoses:
 - A. Plaque psoriasis OR
 - B. Active psoriatic arthritis OR
 - C. Oral ulcers associated with Behcet's disease (BD) AND
3. Patient has had clinical benefit with the requested agent (slowing of disease progression or decrease in symptom severity and/or frequency)

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Formulary conventional agent required for diagnosis of plaque psoriasis

Formulary conventional agents for plaque psoriasis include cyclosporine, methotrexate, tazarotene, topical calcitriol, or topical corticosteroids

NO prerequisites are required for diagnoses of active psoriatic arthritis or oral ulcers associated with Behcet's disease (BD)

Prior Authorization Group Description:

Ozempic PA

Drug Name(s)

Ozempic Inj

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

Requested agent will be used for weight loss alone

Required Medical Information:

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent within the past 180 days OR
 - C. ALL of the following:
 - i. Patient does NOT have any FDA labeled contraindications to the requested agent AND
 - ii. Patient will NOT be using the requested agent in combination with another GLP-1 agonist agent, or an agent containing a GLP-1 agonist AND
 - iii. Patient will NOT be using the requested agent in combination with an agent containing a dipeptidyl peptidase-4 (DPP-4) inhibitor

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Panretin PA

Drug Name(s)

Panretin

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent OR
 - C. ALL of the following:
 - i. ONE of the following:
 1. BOTH of the following:
 - a. Patient has a diagnosis of cutaneous lesions associated with AIDS-related Kaposi's sarcoma (KS) AND
 - b. Patient does NOT require systemic anti-Kaposi's sarcoma therapy OR
 2. Patient has an indication that is supported in CMS approved compendia for the requested agent AND
 - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, dermatologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND
 - iii. Patient does NOT have any FDA labeled contraindications to the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Pegylated Interferon PA

Drug Name(s)

Pegasys

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of chronic hepatitis B AND BOTH of the following:

- i. The chronic hepatitis B infection has been confirmed by serological markers AND
- ii. Patient has NOT been administered the requested agent for more than 48 weeks for the treatment of chronic hepatitis B OR

B. BOTH of the following:

- i. Patient has a diagnosis of chronic hepatitis C confirmed by serological markers AND
- ii. The requested agent will be used in a treatment regimen and length of therapy that is supported in FDA approved labeling for the patient's diagnosis and genotype OR

C. Patient has an indication that is supported in CMS approved compendia for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

12 months for all other diagnoses. For hep B, hep C see Other Criteria

Other Criteria:

No prior peginterferon alfa use, approve 48 weeks for hepatitis B infection. Prior peginterferon alfa use, approve remainder of 48 weeks of total therapy for hepatitis B infection

Duration of therapy for hepatitis C: Based on FDA approved labeling

Prior Authorization Group Description:

Pirfenidone PA

Drug Name(s)

Pirfenidone

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of idiopathic pulmonary fibrosis (IPF) AND
2. Patient has no known explanation for interstitial lung disease (ILD) or pulmonary fibrosis (e.g., radiation, drugs, metal dusts, sarcoidosis, or any connective tissue disease known to cause ILD)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of idiopathic pulmonary fibrosis (IPF) AND
3. Patient has had clinical benefit with the requested agent

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., pathologist, pulmonologist, radiologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Posaconazole PA

Drug Name(s)

Posaconazole

Posaconazole Dr

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of oropharyngeal candidiasis AND ONE of the following:

- i. Patient has tried and had an inadequate response to fluconazole or an alternative antifungal agent OR
- ii. Patient has an intolerance or hypersensitivity to fluconazole or an alternative antifungal agent OR
- iii. Patient has an FDA labeled contraindication to fluconazole or an alternative antifungal agent OR

B. The requested agent is being prescribed for prophylaxis of invasive Aspergillus or Candida AND patient is severely immunocompromised, such as a hematopoietic stem cell transplant [HSCT] recipient, or hematologic malignancy with prolonged neutropenia from chemotherapy, or is a high-risk solid organ (lung, heart-lung, liver, pancreas, small bowel) transplant patient, or long term use of high dose corticosteroids (greater than 1 mg/kg/day of prednisone or equivalent) OR

C. Patient has a diagnosis of invasive Aspergillus AND ONE of the following:

- i. Patient has tried and had an inadequate response to an alternative antifungal agent OR
- ii. Patient has an intolerance or hypersensitivity to an alternative antifungal agent OR
- iii. Patient has an FDA labeled contraindication to an alternative antifungal agent OR

D. Patient has another indication that is supported in CMS approved compendia for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be 1 month for oropharyngeal candidiasis, 6 months for all other indications

Other Criteria:

Criteria for renewal approval require BOTH of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. The requested agent is being prescribed for prophylaxis of invasive Aspergillus or Candida and patient continues to be severely immunocompromised, such as a hematopoietic stem cell

transplant [HSCT] recipient, or hematologic malignancy with prolonged neutropenia from chemotherapy, or is a high-risk solid organ (lung, heart-lung, liver, pancreas, small bowel) transplant patient, or long term use of high dose corticosteroids (greater than 1 mg/kg/day of prednisone or equivalent) OR

B. Patient has a diagnosis of invasive *Aspergillus* AND patient has continued indicators of active disease (e.g., biomarkers in serum assay, microbiologic cultures, radiographic evidence) OR

C. BOTH of the following:

i. Patient has a diagnosis of oropharyngeal candidiasis AND

ii. Patient has had clinical benefit with the requested agent OR

D. BOTH of the following:

i. Patient has another indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient has had clinical benefit with the requested agent

Prior Authorization Group Description:

Promacta PA

Drug Name(s)

Eltrombopag

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

- A. Patient (pt) has a diagnosis of persistent or chronic immune (idiopathic) thrombocytopenia (ITP) AND ONE of the following:
 - i. Pt has tried and had an insufficient response to a corticosteroid or immunoglobulin (IVIg or anti-D) OR
 - ii. Pt has an intolerance or hypersensitivity to a corticosteroid or immunoglobulin (IVIg or anti-D) OR
 - iii. Pt has an FDA labeled contraindication to a corticosteroid or immunoglobulin (IVIg or anti-D) OR
 - iv. Pt has had an insufficient response to a splenectomy OR
- B. Pt has a diagnosis of hepatitis C associated thrombocytopenia AND ONE of the following:
 - i. Pt's platelet count is less than $75 \times 10^9/L$ AND the intent is to increase platelet counts sufficiently to initiate interferon therapy OR
 - ii. Pt is on concomitant therapy with interferon therapy AND is at risk for discontinuing hepatitis C therapy due to thrombocytopenia OR
- C. Pt has a diagnosis of severe aplastic anemia (SAA) AND ALL of the following:
 - i. Pt has at least 2 of the following blood criteria:
 - 1. Neutrophils less than $0.5 \times 10^9/L$ OR
 - 2. Platelets less than $30 \times 10^9/L$ OR
 - 3. Reticulocyte count less than $60 \times 10^9/L$ AND
 - ii. Pt has at least 1 of the following marrow criteria:
 - 1. Severe hypocellularity is less than 25% OR
 - 2. Moderate hypocellularity is 25-50% with hematopoietic cells representing less than 30% of residual cells AND
 - iii. ONE of the following:
 - 1. Pt has tried and had an insufficient response to BOTH antithymocyte globulin (ATG) AND cyclosporine therapy OR
 - 2. BOTH of the following:
 - a. Pt will be using the requested agent as first-line treatment (i.e., has not been treated with ATG and/or cyclosporine) AND
 - b. Pt will use the requested agent in combination with standard immunosuppressive therapy (i.e., ATG AND cyclosporine) OR

Initial criteria continues: see Other Criteria

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Initial: 6 months for ITP. Renewal: 12 months for ITP. Other indications, see Other Criteria.

Other Criteria:

- D. Pt has another indication that is supported in CMS approved compendia for the requested agent AND
- 2. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

Criteria for renewal approval require ALL of the following:

- 1. Pt has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. ONE of the following:
 - A. Pt has a diagnosis of persistent or chronic immune (idiopathic) thrombocytopenia (ITP) AND ONE of the following:
 - i. Pt's platelet count is $50 \times 10^9/L$ or greater OR
 - ii. Pt's platelet count has increased sufficiently to avoid clinically significant bleeding OR
 - B. Pt has a diagnosis of hepatitis C associated thrombocytopenia AND BOTH of the following:
 - i. ONE of the following:
 - 1. Pt will be initiating hepatitis C therapy with interferon therapy OR
 - 2. Pt will be maintaining hepatitis C therapy with interferon therapy at the same time as the requested agent AND
 - ii. ONE of the following:
 - 1. Pt's platelet count is $90 \times 10^9/L$ or greater OR
 - 2. Pt's platelet count has increased sufficiently to initiate or maintain interferon therapy for the treatment of hepatitis C OR
 - C. Pt has a diagnosis of severe aplastic anemia (SAA) AND the pt has had clinical benefit with the requested agent OR
 - D. Pt has another indication that is supported in CMS approved compendia and the pt has had clinical benefit with the requested agent AND
- 3. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

Initial: 48 weeks for hepatitis C associated thrombocytopenia, 6 months for first-line therapy in severe aplastic anemia, 16 weeks for SAA, 12 months for All other indications

Renewal: 48 weeks for hepatitis C associated thrombocytopenia, 12 months for SAA, 12 months for All other indications

Prior Authorization Group Description:

Pulmonary Hypertension PA – Adempas

Drug Name(s)

Adempas

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND

ii. Patient has an FDA labeled indication for the requested agent OR

B. Patient has a diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group 4, as determined by a ventilation-perfusion scan and a confirmatory selective pulmonary angiography AND ALL of the following:

i. ONE of the following:

- a. Patient is NOT a candidate for surgery OR
- b. Patient has had pulmonary endarterectomy AND has persistent or recurrent disease AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units OR

C. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

i. Patient's World Health Organization (WHO) functional class is II or greater AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND

Initial criteria continues: see Other Criteria

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

v. ONE of the following:

- a. The requested agent will be utilized as monotherapy OR
- b. The requested agent will be utilized for add-on therapy to existing monotherapy (dual therapy), AND BOTH of the following:
 - 1. Patient has unacceptable or deteriorating clinical status despite established pharmacotherapy AND
 - 2. The requested agent is in a different therapeutic class OR
- c. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy), AND BOTH of the following:
 - 1. Patient has unacceptable or deteriorating clinical status despite established pharmacotherapy AND
 - 2. All three agents in the triple therapy are from a different therapeutic class

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent

Prior Authorization Group Description:

Pulmonary Hypertension PA – Ambrisentan

Drug Name(s)

Ambrisentan

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND

ii. Patient has an FDA labeled indication for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

i. Patient's World Health Organization (WHO) functional class is II or greater AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND

v. ONE of the following:

a. The requested agent will be utilized as monotherapy OR

b. The requested agent will be used in combination with a phosphodiesterase 5 (PDE5) inhibitor for dual therapy ONLY OR

c. The requested agent will be utilized for add-on therapy to existing monotherapy (dual therapy), [except for dual therapy requests for a phosphodiesterase 5 (PDE 5) inhibitor plus an endothelin receptor antagonist (ERA)], AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

2. The requested agent is in a different therapeutic class OR

Initial criteria continues: see Other Criteria

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

d. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy), AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
2. All three agents in the triple therapy are from a different therapeutic class OR

e. The requested agent will be utilized as part of triple therapy in a treatment naive patient AND BOTH of the following:

1. Patient is classified as WHO functional class IV or has been assessed as high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
2. The three agents being utilized consist of: ERA plus PDE5i plus prostanoid

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent

Prior Authorization Group Description:

Pulmonary Hypertension PA – Bosentan

Drug Name(s)

Bosentan

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

Elevated liver enzymes accompanied by signs or symptoms of liver dysfunction/injury or a bilirubin level of 2 times the ULN (upper limit of normal) or greater AND FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require the following:

1. ONE of the following:
 - A. BOTH of the following:
 - i. ONE of the following:
 - a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND
 - ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR
 - B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1, as determined by right heart catheterization, AND ALL of the following:
 - i. Patient's World Health Organization (WHO) functional class is II or greater AND
 - ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND
 - iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND
 - iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND
 - v. ONE of the following:
 - a. The requested agent will be utilized as monotherapy OR
 - b. The requested agent will be used in combination with a phosphodiesterase 5 (PDE5) inhibitor for dual therapy ONLY OR
 - c. The requested agent will be utilized for add-on therapy to existing monotherapy (dual therapy), [except for dual therapy requests for a phosphodiesterase 5 inhibitor (PDE5) plus an endothelin receptor antagonist (ERA)], AND BOTH of the following:
 1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
 2. The requested agent is in a different therapeutic class OR

Initial criteria continues: see Other Criteria

Age Restriction:

Prescriber Restrictions:

Coverage Duration:

Approval will be for 12 months

Other Criteria:

- d. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy), AND BOTH of the following:
 - 1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
 - 2. All three agents in the triple therapy are from a different therapeutic class OR
 - e. The requested agent will be utilized as part of triple therapy in a treatment naive patient AND BOTH of the following:
 - 1. Patient is classified as WHO functional class IV or has been assessed as high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
 - 2. The three agents being utilized consist of: ERA plus PDE5i plus prostanoid OR
- C. Patient has an indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent

Prior Authorization Group Description:

Pulmonary Hypertension PA – Orenitram

Drug Name(s)

Orenitram

Orenitram Titration Kit

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND

ii. Patient has an FDA labeled indication for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

i. Patient's World Health Organization (WHO) functional class is II or greater AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND

v. ONE of the following:

a. The requested agent will be utilized as monotherapy OR

b. The requested agent will be utilized for add-on therapy to existing monotherapy (dual therapy), AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

2. The requested agent is in a different therapeutic class OR

c. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy), AND ALL of the following:

1. Patient is WHO functional class III or IV or has been assessed as intermediate to high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND

2. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

3. All three agents in the triple therapy are from a different therapeutic class OR

Initial criteria continues: see Other Criteria

Age Restriction:

Prescriber Restrictions:

Coverage Duration:

Approval will be for 12 months

Other Criteria:

- d. The requested agent will be utilized as part of triple therapy in a treatment naive patient AND BOTH of the following:
 - 1. Patient is classified as WHO functional class IV or has been assessed as high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
 - 2. The three agents being utilized consist of: ERA plus PDE5i plus prostanoid OR
- e. The requested agent will be utilized for add-on therapy to existing triple therapy (quadruple therapy), AND ALL of the following:
 - 1. Patient is WHO functional class III or IV or has been assessed as intermediate to high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
 - 2. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
 - 3. All four agents in the quadruple therapy are from a different therapeutic class

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent

Prior Authorization Group Description:

Pulmonary Hypertension PA – Sildenafil

Drug Name(s)

Sildenafil Citrate

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

Concurrently taking another phosphodiesterase 5 (PDE5) inhibitor with the requested agent AND FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

- i. Patient's World Health Organization (WHO) functional class is II or greater AND
- ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND
- iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND
- iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND
- v. ONE of the following:
 - a. The requested agent will be utilized as monotherapy OR
 - b. The requested agent will be used in combination with an endothelin receptor antagonist (ERA) for dual therapy ONLY OR
 - c. The requested agent will be utilized for add-on therapy to existing monotherapy, [except for dual requests for a phosphodiesterase 5 (PDE5) inhibitor plus an endothelin receptor antagonist (ERA)], AND BOTH of the following:
 - 1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
 - 2. The requested agent is in a different therapeutic class OR

Initial criteria continues: see Other Criteria

Age Restriction:**Prescriber Restrictions:**

Coverage Duration:

Approval will be for 12 months

Other Criteria:

- d. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy) AND BOTH of the following:
 - 1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
 - 2. All three agents in the triple therapy are from a different therapeutic class OR
 - e. The requested agent will be utilized as part of triple therapy in a treatment naive patient AND BOTH of the following:
 - 1. Patient is classified as WHO functional class IV or has been assessed as high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
 - 2. The three agents being utilized consist of: ERA plus PDE5i plus prostanoid OR
- C. Patient has an indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent

Prior Authorization Group Description:

Pulmonary Hypertension PA – Tadalafil

Drug Name(s)

Tadalafil Tablet 20Mg

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

Concurrently taking another phosphodiesterase 5 (PDE5) inhibitor with the requested agent AND FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require the following:

1. ONE of the following:
 - A. BOTH of the following:
 - i. ONE of the following:
 - a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND
 - ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR
 - B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:
 - i. Patient's World Health Organization (WHO) functional class is II or greater AND
 - ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND
 - iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND
 - iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND
 - v. ONE of the following:
 - a. The requested agent will be utilized as monotherapy OR
 - b. The requested agent will be used in combination with an endothelin receptor antagonist (ERA) for dual therapy ONLY OR
 - c. The requested agent will be utilized for add-on therapy to existing monotherapy, [except for dual requests for a phosphodiesterase 5 (PDE5) inhibitor plus an endothelin receptor antagonist (ERA)], AND BOTH of the following:
 1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
 2. The requested agent is in a different therapeutic class OR

Initial criteria continues: see Other Criteria

Age Restriction:**Prescriber Restrictions:**

Coverage Duration:

Approval will be for 12 months

Other Criteria:

- d. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy) AND BOTH of the following:
 - 1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
 - 2. All three agents in the triple therapy are from a different therapeutic class OR
 - e. The requested agent will be utilized as part of triple therapy in a treatment naive patient AND BOTH of the following:
 - 1. Patient is classified as WHO functional class IV or has been assessed as high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
 - 2. The three agents being utilized consist of: ERA plus PDE5i plus prostanoid OR
- C. Patient has an indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent

Prior Authorization Group Description:

Pulmonary Hypertension PA – Winrevair

Drug Name(s)

Winrevair

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND

ii. Patient has an FDA labeled indication for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

- i. Patient's World Health Organization (WHO) functional class is II or greater AND
- ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND
- iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND
- iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND
- v. ALL of the following:
 - a. The requested agent will be utilized for add-on therapy AND
 - b. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
 - c. All agents in the therapy are from a different therapeutic class

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Pyrimethamine PA

Drug Name(s)

Pyrimethamine

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 6 months

Other Criteria:

Prior Authorization Group Description:

Pyrukynd PA

Drug Name(s)

Pyrukynd

Pyrukynd Taper Pack

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. Patient has a diagnosis of hemolytic anemia with pyruvate kinase deficiency (PKD) AND ALL of the following:
 - A. ONE of the following:
 - i. Genetic testing showing a pathogenic PKLR gene mutation OR
 - ii. Patient does NOT have two known pathogenic mutations in the PKLR gene, AND patient has a decrease in pyruvate kinase enzyme activity AND
 - B. Patient is NOT homozygous for the c.1436G to A (p.R479H) variant AND
 - C. Patient has at least 2 variant alleles in the PKLR gene, of which at least 1 is a missense variant AND
 - D. Patient does NOT have two non-missense mutations

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hemolytic anemia with pyruvate kinase deficiency (PKD) AND
3. Patient has had clinical benefit with the requested agent

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., hematologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Quinine PA

Drug Name(s)

Quinine Sulfate

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require the following:

1. Patient has ONE of the following diagnoses:

A. Uncomplicated malaria OR

B. Babesiosis OR

C. An indication that is supported in CMS approved compendia for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be 7 days for malaria, 12 months for all other diagnoses

Other Criteria:

Prior Authorization Group Description:

Repatha PA

Drug Name(s)

Repatha

Repatha Sureclick

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has ONE of the following:

A. A diagnosis of heterozygous familial hypercholesterolemia (HeFH) AND ONE of the following:

- i. Genetic confirmation of one mutant allele at the LDLR, Apo-B, PCSK9, or 1/LDLRAP1 gene OR
- ii. ONE of the following:
 - a. Patient is 18 years of age or older AND has a pretreatment LDL-C greater than 190 mg/dL (greater than 4.9 mmol/L) OR
 - b. Patient is between the ages of 10 and less than 18 years of age AND has a pretreatment LDL-C greater than 155 mg/dL (greater than 4.0 mmol/L) OR
- iii. Clinical manifestations of HeFH (e.g., cutaneous xanthomas, tendon xanthomas, corneal arcus, tuberous xanthoma, or xanthelasma) OR
- iv. "Definite" or "possible" familial hypercholesterolemia as defined by the Simon Broome criteria OR
- v. A Dutch Lipid Clinic Network criteria score of greater than 5 OR

B. A diagnosis of homozygous familial hypercholesterolemia (HoFH) AND ONE of the following:

- i. Genetic confirmation of bi-allelic pathogenic/likely pathogenic variants on different chromosomes at the LDLR, Apo-B, PCSK9, or LDLRAP1 genes or greater than or equal to 2 such variants at different loci OR
- ii. History of untreated LDL-C 400 mg/dL or greater (10 mmol/L or greater) AND ONE of the following:
 - a. Cutaneous or tendon xanthomas before 20 years of age OR
 - b. Untreated elevated LDL-C levels consistent with heterozygous familial hypercholesterolemia (HeFH) in both parents (or in digenic form, one parent may have normal LDL-C levels and the other may have LDL-C levels consistent with HoFH) OR

Initial criteria continues: see Other Criteria

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

- C. An increased risk of major adverse cardiovascular (CV) events [CV death, myocardial infarction (MI), stroke, unstable angina requiring hospitalization, or coronary revascularization] AND the requested agent will be used to reduce the risk of these events OR
 - D. A diagnosis of hypercholesterolemia [not associated with HeFH, HoFH, or increased risk of major adverse cardiovascular (CV) events] OR
 - E. Patient has another indication that is supported in CMS approved compendia for the requested agent AND
- 2. ONE of the following:
 - A. Patient has tried and had an inadequate response to a high-intensity statin (i.e., rosuvastatin 20-40 mg or atorvastatin 40-80 mg) OR
 - B. Patient has an intolerance to TWO different statins OR
 - C. Patient has an FDA labeled contraindication to a statin AND
 - 3. Patient will NOT be using the requested agent in combination with another PCSK9 agent

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent AND
- 4. Patient will NOT be using the requested agent in combination with another PCSK9 agent

Prior Authorization Group Description:

Revcovi PA

Drug Name(s)

Revcovi

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of adenosine deaminase severe combined immune deficiency (ADA-SCID) confirmed by ONE of the following:
 - A. Molecular genetic confirmation of mutations in both alleles of the ADA1 gene OR
 - B. Deficiency or absence of ADA in lysed erythrocytes, fibroblasts (cultured from amniotic fluid), or chorionic villus OR
 - C. Positive screening by T cell receptor excision circles (TRECs) OR
 - D. Increase in deoxyadenosine triphosphate (dATP) levels in erythrocyte lysates over the testing laboratory's upper limit of the normal range AND
2. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of adenosine deaminase severe combined immune deficiency (ADA-SCID) AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., geneticist, hematologist, immunologist, oncologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Rezdiffra PA

Drug Name(s)

Rezdiffra

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

Decompensated cirrhosis AND Moderate to severe hepatic impairment (Child-Pugh Class B or C)

Required Medical Information:

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis AND
2. Patient has stage F2 or F3 fibrosis as confirmed by BOTH of the following (prior to therapy with the requested agent):
 - A. A FIB-4 score consistent with stage F2 or F3 fibrosis adjusted for age AND
 - B. ONE of the following:
 - i. A liver biopsy OR
 - ii. ONE of the following:
 1. Vibration-controlled transient elastography (VCTE, e.g., Fibroscan) OR
 2. Enhanced liver fibrosis (ELF) OR
 3. Magnetic resonance elastography (MRE)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis AND
3. Patient has had clinical benefit with the requested agent

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., hepatologist, gastroenterologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Ritalin PA

Drug Name(s)

Methylphenidate Hcl (Ritalin)

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Roflumilast PA

Drug Name(s)

Roflumilast

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. Patient is currently being treated with a long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination with or without an inhaled corticosteroid (ICS) OR
 - B. Patient has an intolerance or hypersensitivity to a long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination OR
 - C. Patient has an FDA labeled contraindication to a long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Rybelsus PA

Drug Name(s)

Ozempic Tab

Rybelsus

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

Requested agent will be used for weight loss alone

Required Medical Information:

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent within the past 180 days OR
 - C. ALL of the following:
 - i. Patient does NOT have any FDA labeled contraindications to the requested agent AND
 - ii. Patient will NOT be using the requested agent in combination with another GLP-1 agonist agent, or an agent containing a GLP-1 agonist AND
 - iii. Patient will NOT be using the requested agent in combination with an agent containing a dipeptidyl peptidase-4 (DPP-4) inhibitor

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Sapropterin PA

Drug Name(s)

Sapropterin Dihydrochloride

Zelvysia

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of phenylketonuria (PKU) AND
2. Prescriber has submitted a baseline blood Phe level measured prior to initiation of therapy with the requested agent, which is above the recommended levels indicated for the patient's age range or condition AND
3. Patient will NOT be using the requested agent in combination with Palynziq (pegvaliase-pqpz) for the requested indication AND
4. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of phenylketonuria (PKU) AND
3. ONE of the following:
 - a. Patient's blood Phe levels are being maintained within the acceptable range OR
 - b. Patient has had a decrease in blood Phe level from baseline AND
4. Patient will NOT be using the requested agent in combination with Palynziq (pegvaliase-pqpz) for the requested indication AND
5. The requested dose is within FDA labeled dosing for the requested indication

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., metabolic or genetic disorders) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Initial: 2 months if dose is 5 to less than 20 mg/kg/day, 1 month if 20 mg/kg/day Renewal: 12 months

Other Criteria:

Prior Authorization Group Description:

Self - Administered Oncology PA

Drug Name(s)

Abiraterone Acetate
Abirtega
Akeega
Alecensa
Alunbrig
Augtyro
Avmapki Fakzynja Co-Pack
Ayvakit
Balversa
Besremi
Bexarotene Capsules
Bosulif
Braftovi
Brukinsa
Cabometyx
Calquence
Caprelsa
Cometriq
Copiktra
Cotellic
Danziten
Dasatinib
Daurismo
Ensacove
Erivedge
Erleada
Erlotinib Hcl
Everolimus
Fotivda
Fruzaqla
Gavreto
Gefitinib
Gilotrif
Gomekli
Hernexeos
Hyrnuo
Ibrance
Ibtrozi
Iclusig
Idhifa

Imatinib Mesylate
Imbruvica
Imkeldi
Inluriyo
Inlyta
Inqovi
Inrebic
Itovebi
Iwilfin
Jakafi
Jaypirca
Kisqali
Kisqali Femara
Komzifti
Koselugo
Krazati
Lapatinib Ditosylate
Lazcluze
Lenalidomide
Lenvima
Lifyorli
Lonsurf
Lorbrena
Lumakras
Lynparza
Lytgobi
Matulane
Mekinist
Mektovi
Modeyso
Nerlynx
Nilotinib
Ninlaro
Nubeqa
Odomzo
Ogsiveo
Ojemda
Ojjaara
Onureg
Orgovyx
Orserdu
Pazopanib Hcl
Pemazyre

Piqray
Pomalidomide
Qinlock
Retevmo
Revuforj
Rezlidhia
Romvimza
Rozlytrek
Rubraca
Rydapt
Scemblix
Sorafenib
Stivarga
Sunitinib Malate
Tabrecta
Tafinlar
Tagrisso
Talzenna
Tepmetko
Thalomid
Tibsovo
Torpenz
Tretinoin Capsule
Truqap
Tukysa
Turalio
Vanflyta
Venclexta
Venclexta Starting Pack
Verzenio
Vitrakvi
Vizimpro
Vonjo
Voranigo
Welireg
Xalkori
Xospata
Xpovio
Xtandi
Zejula
Zelboraf
Zolinza
Zydelig
Zykadia

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR

B. Prescriber states the patient is currently being treated with the requested agent OR

C. ALL of the following:

i. Genetic testing has been completed, if required, for therapy with the requested agent and results indicate the requested agent is appropriate AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent AND

iii. ONE of the following:

a. The requested agent is FDA labeled or supported by CMS approved compendia as a first-line therapy for the requested indication OR

b. Patient has tried appropriate FDA labeled or CMS approved compendia supported therapy that are indicated as first-line therapy for the requested indication OR

c. Patient has an intolerance or hypersensitivity to the first-line therapy for the requested indication OR

d. Patient has an FDA labeled contraindication to the first-line therapy for the requested indication AND

iv. Patient does NOT have any FDA labeled limitations of use that is not otherwise supported in NCCN guidelines AND

Criteria continues: see Other Criteria

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

v. ONE of the following:

a. The requested agent is not Bosulif OR

b. The requested agent is Bosulif AND ONE of the following:

1. Patient's medication history indicates use of imatinib OR dasatinib for the requested indication (if applicable) OR

2. Patient has an intolerance or hypersensitivity to imatinib OR dasatinib OR

3. Patient has an FDA labeled contraindication to imatinib OR dasatinib OR

- 4. CMS approved compendia does not support the use of imatinib OR dasatinib for the requested indication OR
 - 5. Prescriber has provided information in support of use of Bosulif over imatinib OR dasatinib for the requested indication AND
- vi. ONE of the following:
 - a. The requested agent is not Ojjaara OR Inrebic OR
 - b. The requested agent is Ojjaara OR Inrebic AND ONE of the following:
 - 1. Patient's medication history indicates use of Jakafi for the requested indication (if applicable) OR
 - 2. Patient has an intolerance or hypersensitivity to Jakafi OR
 - 3. Patient has an FDA labeled contraindication to Jakafi OR
 - 4. CMS approved compendia does not support the use of Jakafi for the requested indication OR
 - 5. Prescriber has provided information in support of use of Ojjaara OR Inrebic over Jakafi for the requested indication

Prior Authorization Group Description:

Signifor PA

Drug Name(s)

Signifor

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

Severe hepatic impairment (i.e., Child Pugh C)

Required Medical Information:

Criteria for initial approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of acromegaly AND ONE of the following:

i. Patient had an inadequate response to surgery as indicated by growth hormone and serum IGF-1 levels that are above the reference ranges for the patient's gender and age
OR

ii. Patient is NOT a candidate for surgery OR

B. Patient has a diagnosis of Cushing's disease (CD) AND ONE of the following:

i. Patient had an inadequate response to pituitary surgical resection OR

ii. Patient is NOT a candidate for pituitary surgical resection OR

C. Patient has an indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require BOTH of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of acromegaly AND ONE of the following:

i. Patient has growth hormone and serum IGF-1 levels that are within normal limits for patient's gender and age reference range OR

ii. Patient has had clinical improvement (e.g., reduction in tumor size, decreased headaches, improved cardiovascular or respiratory symptoms) OR

B. Patient has a diagnosis of Cushing's disease (CD) AND BOTH of the following:

i. Patient has a urinary free cortisol level less than or equal to the upper limit of normal
AND

ii. Patient has had improvement in at least ONE of the following clinical signs and symptoms:

1. Fasting plasma glucose OR

2. Hemoglobin A1c OR

3. Hypertension OR

4. Weight OR

C. BOTH of the following:

i. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient has had clinical benefit with the requested agent

Age Restriction:

Prescriber Restrictions:

Coverage Duration:

Initial: Acromegaly - 6 months, CD - 7 months, All other diagnoses - 12 months, Renewal: 12 months

Other Criteria:

Prior Authorization Group Description:

Sivextro PA

Drug Name(s)

Sivextro

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has ONE of the following:

A. BOTH of the following:

- i. A documented acute bacterial skin and skin structure infection (ABSSSI) defined as a bacterial infection of the skin with a lesion size area of at least 75 cm² (lesion size measured by the area of redness, edema, or induration) AND
- ii. The infection is due to *Staphylococcus aureus*, *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus anginosus*, *Streptococcus intermedius*, *Streptococcus constellatus*, or *Enterococcus faecalis* OR

B. Another indication that is supported in CMS approved compendia for the requested agent
AND

2. ONE of the following:

A. The requested agent is prescribed by an infectious disease specialist or the prescriber has consulted with an infectious disease specialist on treatment of this patient OR

B. The requested agent is NOT prescribed by an infectious disease specialist or the prescriber has NOT consulted with an infectious disease specialist on treatment of this patient AND ONE of the following:

- i. There is documentation of resistance to TWO of the following: beta-lactams, macrolides, clindamycin, tetracycline, or co-trimoxazole at the site of infection OR
- ii. Patient has an intolerance or hypersensitivity to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole OR
- iii. Patient has an FDA labeled contraindication to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole OR
- iv. There is documentation of resistance to vancomycin at the site of infection OR
- v. Patient has an intolerance or hypersensitivity to vancomycin OR
- vi. Patient has an FDA labeled contraindication to vancomycin AND

3. Patient will NOT be using the requested agent in combination with linezolid for the same infection
AND

4. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

Age Restriction:

Patient is within the FDA labeled age for the requested agent

Prescriber Restrictions:**Coverage Duration:**

Approval will be 6 days for ABSSSI or 30 days for all other indications

Other Criteria:

Prior Authorization Group Description:

Sodium Oxybate PA

Drug Name(s)

Sodium Oxybate

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of narcolepsy with cataplexy OR

B. BOTH of the following:

i. Patient has a diagnosis of narcolepsy with excessive daytime sleepiness AND

ii. ONE of the following:

a. Patient is between the ages of 7 and less than 18 years OR

b. BOTH of the following:

1. Patient is 18 years of age or over AND

2. ONE of the following:

a) Patient has tried and had an inadequate response to modafinil or armodafinil OR

b) Patient has an intolerance or hypersensitivity to modafinil or armodafinil OR

c) Patient has an FDA labeled contraindication to modafinil or armodafinil OR

C. Patient has another indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of narcolepsy with cataplexy OR

B. Patient has a diagnosis of narcolepsy with excessive daytime sleepiness OR

C. Patient has another indication that is supported in CMS approved compendia for the requested agent AND

3. Patient has had clinical benefit with the requested agent

Age Restriction:

For diagnosis of narcolepsy with cataplexy, patient is 7 years of age or over. For diagnosis of narcolepsy with excessive daytime sleepiness, patient is 7 years of age or over.

Prescriber Restrictions:**Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Somatostatin Analogs PA – Lanreotide

Drug Name(s)

Somatuline Depot

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND ONE of the following:

- i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
- ii. Prescriber states the patient is currently being treated with the requested agent OR

B. ONE of the following:

i. Patient has a diagnosis of acromegaly AND ONE of the following:

- a. Patient is not a candidate for surgical resection or pituitary radiation therapy OR
- b. The requested agent is for adjunctive therapy with pituitary radiation therapy OR
- c. Patient had an inadequate response to surgery or pituitary radiation therapy as indicated by growth hormone levels or serum IGF-1 levels that are above the reference range OR

ii. Patient has a diagnosis of gastroenteropancreatic neuroendocrine tumors AND BOTH of the following:

- a. The tumors are well or moderately differentiated AND
- b. ONE of the following:
 - 1. The tumors are unresectable, locally advanced OR
 - 2. Patient has metastatic disease OR

iii. Patient has a diagnosis of carcinoid syndrome OR

iv. Patient has another indication that is supported in CMS approved compendia for the requested agent AND

2. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

Other Criteria:

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
3. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent OR
 - C. BOTH of the following:
 - i. ONE of the following:
 1. Patient has a diagnosis of acromegaly OR
 2. Patient has a diagnosis of metastatic OR unresectable, locally advanced, well or moderately differentiated gastroenteropancreatic neuroendocrine tumors OR
 3. Patient has a diagnosis of carcinoid syndrome OR
 4. Patient has another indication that is supported in CMS approved compendia for the requested agent AND
 - ii. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

Prior Authorization Group Description:

Somatostatin Analogs PA – Octreotide

Drug Name(s)

Octreotide Acetate

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND ONE of the following:

- i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- ii. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR

B. ONE of the following:

i. Patient has a diagnosis of acromegaly AND ONE of the following:

- a. Patient is not a candidate for surgical resection or pituitary radiation therapy OR
- b. The requested agent is for adjunctive therapy with pituitary radiation therapy OR
- c. Patient had an inadequate response to surgery or pituitary radiation therapy as indicated by growth hormone levels or serum IGF-1 levels that are above the reference range OR

ii. Patient has severe diarrhea and/or flushing episodes associated with metastatic carcinoid tumors OR

iii. Patient has profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors OR

iv. Patient has a diagnosis of dumping syndrome AND ONE of the following:

- a. Patient has tried and had an inadequate response to acarbose OR
- b. Patient has an intolerance or hypersensitivity to acarbose OR
- c. Patient has an FDA labeled contraindication to acarbose OR

v. Patient has another indication that is supported in CMS approved compendia for the requested agent AND

2. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

Other Criteria:

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
 - A. Patient has a diagnosis of acromegaly OR
 - B. Patient has severe diarrhea and/or flushing episodes associated with metastatic carcinoid tumors OR
 - C. Patient has profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors OR
 - D. Patient has a diagnosis of dumping syndrome OR
 - E. Patient has another indication that is supported in CMS approved compendia for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

Prior Authorization Group Description:

Somatostatin Analogs PA – Somavert

Drug Name(s)

Somavert

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of acromegaly AND ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
 - C. BOTH of the following:
 - i. ONE of the following:
 - a. Patient is not a candidate for surgical resection or pituitary radiation therapy OR
 - b. The requested agent is for adjunctive therapy with pituitary radiation therapy OR
 - c. Patient had an inadequate response to surgery or pituitary radiation therapy as indicated by serum IGF-1 levels that are above the reference range AND
 - ii. ONE of the following:
 - a. Patient has tried and had an inadequate response to octreotide or lanreotide OR
 - b. Patient has an intolerance or hypersensitivity to octreotide or lanreotide OR
 - c. Patient has an FDA labeled contraindication to octreotide or lanreotide AND
2. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of acromegaly AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Stoboclo PA

Drug Name(s)

Stoboclo

Indications:

All FDA-Approved Indications, Some Medically-Accepted Indications.

Off-Label Uses:

Osteopenia (osteoporosis prophylaxis)

Exclusion Criteria:

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require ALL of:

1. ONE of:

A. Patient's (pt) sex is male or the pt is postmenopausal with a diagnosis of osteoporosis AND BOTH of:

i. Pt's diagnosis was confirmed by ONE of:

1. A fragility fracture in the hip or spine OR
2. A T-score of -2.5 or lower OR
3. A T-score of -1.0 to -2.5 AND ONE of:
 - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
 - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
 - c. A FRAX 10-year probability of hip fracture of 3% or greater AND

ii. ONE of:

1. Pt is at a very high fracture risk as defined by ONE of:
 - a. Pt had a recent fracture (within the past 12 months) OR
 - b. Pt had fractures while on FDA approved osteoporosis therapy OR
 - c. Pt has had multiple fractures OR
 - d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
 - e. Pt has a very low T-score (less than -3.0) OR
 - f. Pt is at high risk for falls or has a history of injurious falls OR
 - g. Pt has a very high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%) or by other validated fracture risk algorithm OR
2. ONE of:
 - a. Pt's medication history includes use of a bisphosphonate OR
 - b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR

B. Pt is requesting the agent for osteopenia (osteoporosis prophylaxis) AND ALL of:

i. ONE of:

1. Pt's sex is male and the pt is 50 years of age or over OR
2. Pt is postmenopausal AND

- ii. Pt has a T-score between -1.0 to -2.50 AND
- iii. ONE of:
 - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
 - b. 10-year probability of a hip fracture 3% and greater per FRAX OR
 - c. 10-year probability of a major OP-related fracture 20% and greater per FRAX AND
- iv. ONE of:
 - a. Pt's medication history includes use of a bisphosphonate OR

Criteria continues: See Other Criteria

Age Restriction:

Prescriber Restrictions:

Coverage Duration:

Approval will be for 12 months

Other Criteria:

- b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- C. Pt's sex is a female with a diagnosis of breast cancer who is receiving aromatase inhibitor therapy AND ONE of:
 - i. Pt's medication history includes use of a bisphosphonate OR
 - ii. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- D. Pt's sex is male with a diagnosis of prostate cancer receiving androgen deprivation therapy (ADT) AND ONE of:
 - i. Pt's medication history includes use of a bisphosphonate OR
 - ii. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- E. Pt has a diagnosis of glucocorticoid-induced osteoporosis AND ALL of:
 - i. Pt is either initiating or continuing systemic glucocorticoids in a daily dose equivalent to 7.5 mg or greater of prednisone AND
 - ii. Pt is expected to remain on glucocorticoids for at least 6 months AND
 - iii. Pt's diagnosis was confirmed by ONE of:
 - 1. A fragility fracture in the hip or spine OR
 - 2. A T-score of -2.5 or lower OR
 - 3. A T-score of -1.0 to -2.5 AND ONE of:
 - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
 - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
 - c. A FRAX 10-year probability of hip fracture of 3% or greater AND
 - iv. ONE of:
 - 1. Pt is at high fracture risk as defined by ONE of:
 - a. Pt had a recent fracture (within the past 12 months) OR
 - b. Pt had fractures while on FDA approved osteoporosis therapy OR

- c. Pt has had multiple fractures OR
- d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
- e. Pt has a very low T-score (less than -2.5) OR
- f. Pt is at high risk for falls or has a history of injurious falls OR
- g. Pt has a high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 20%, hip fracture greater than 3%) or by other validated fracture risk algorithm OR

2. ONE of:

- a. Pt's medication history includes use of a bisphosphonate OR
- b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate AND

2. ONE of:

- A. Pt has a pretreatment or current calcium level that is NOT below the lower limit of the testing laboratory's normal range OR
- B. Pt has a pretreatment or current calcium level that is below the lower limit of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
- C. Prescriber has indicated that the pt is not at risk for hypocalcemia (not including risk associated with the requested agent) AND

3. Pt will NOT be using the requested agent in combination with a bisphosphonate, another form of denosumab, romosozumab-aqqg, or parathyroid hormone analog (e.g., abaloparatide, teriparatide) for the requested indication AND

4. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

Prior Authorization Group Description:

Strensiq PA

Drug Name(s)

Strensiq

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has ONE of the following diagnoses:
 - A. Perinatal or infantile-onset hypophosphatasia OR
 - B. Juvenile-onset hypophosphatasia AND
2. Patient has documentation (i.e., medical records) of clinical manifestations to support the diagnosis of hypophosphatasia at the age of onset prior to age 18 (e.g., vitamin B6-dependent seizures, skeletal abnormalities such as rachitic chest deformity leading to respiratory problems or bowed arms/legs, “failure to thrive”) AND
3. Patient has documentation (i.e., medical records) of radiographic imaging to support the diagnosis of hypophosphatasia at the age of onset prior to age 18 (e.g., infantile rickets, alveolar bone loss, craniosynostosis, fractures) AND
4. Patient has documentation (i.e., medical records) of confirmed mutation(s) in the ALPL gene that encodes the tissue non-specific isoenzyme of alkaline phosphatase (TNSALP) AND
5. Patient has documentation (i.e., medical records) of a measured total serum alkaline phosphatase (ALP) level that is below the normal lab reference range for age and sex AND
6. Patient has documentation (i.e., medical records) of ONE of the following:
 - A. Elevated urine concentration of phosphoethanolamine (PEA) OR
 - B. Elevated serum concentration of pyridoxal 5'-phosphate (PLP) in the absence of vitamin supplements within one week prior to the test OR
 - C. Elevated urinary inorganic pyrophosphate (PPi) AND
7. The requested dose is within FDA labeled dosing (based on the patient’s weight) for the requested indication

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient’s diagnosis (e.g., endocrinologist or geneticist with expertise in metabolic bone diseases) or the prescriber has consulted with a specialist in the area of the patient’s diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan’s Prior Authorization criteria AND
2. Patient has ONE of the following diagnoses:
 - A. Perinatal or infantile-onset hypophosphatasia OR

- B. Juvenile-onset hypophosphatasia AND
- 3. There is documentation (i.e., medical records) that the patient has had a decrease from baseline (before treatment with the requested agent) in at least ONE of the following levels:
 - A. Urine concentration of phosphoethanolamine (PEA) OR
 - B. Serum concentration of pyridoxal 5'-phosphate (PLP) in the absence of vitamin supplements within one week prior to the test OR
 - C. Urinary inorganic pyrophosphate (PPI) AND
- 4. Patient has documentation (i.e., medical records) of clinical improvement and/or stabilization with the requested agent (e.g., improvement in respiratory status, growth, pain, radiographic findings, other symptoms associated with the disease) AND
- 5. The requested dose is within FDA labeled dosing (based on the patient's weight) for the requested indication

Prior Authorization Group Description:

Substrate Reduction Therapy PA – Miglustat

Drug Name(s)

Miglustat

Yargesa

Indications:

All FDA-Approved Indications, Some Medically-Accepted Indications.

Off-Label Uses:

Niemann-Pick disease type C (NPC)

Exclusion Criteria:**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

- i. Patient has a diagnosis of Gaucher disease type 1 (GD1) confirmed by ONE of the following:
 - a. A baseline (prior to therapy for the requested indication) glucocerebrosidase enzyme activity of less than or equal to 15% of mean normal in peripheral blood leukocytes, fibroblasts, or other nucleated cells OR
 - b. Confirmation of genetic mutation of the glucocerebrosidase (GBA) gene with two disease-causing alleles AND
- ii. Prior to any treatment for the intended diagnosis, the patient has had at least ONE of the following clinical presentations:
 - a. Anemia [defined as mean hemoglobin (Hb) level below the testing laboratory's lower limit of the normal range based on age and gender] OR
 - b. Thrombocytopenia (defined as platelet count of less than 100,000 per microliter) OR
 - c. Hepatomegaly OR
 - d. Splenomegaly OR
 - e. Growth failure (i.e., growth velocity is below the standard mean for age) OR
 - f. Evidence of bone disease with other causes ruled out OR

B. ALL of the following:

- i. Patient has a diagnosis of Niemann-Pick disease type C (NPC) as confirmed by genetic analysis mutation in the NPC1 or NPC2 genes AND
- ii. The requested agent will be used for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) AND
- iii. The requested agent will be used in combination with Miplyffa (arimoclomol)

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, gastroenterologist, geneticist, hematologist, hepatologist, neurologist, specialist in metabolic diseases) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following
 - A. Patient has a diagnosis of Gaucher disease type 1 (GD1) OR
 - B. ALL of the following:
 - i. Patient has a diagnosis of Niemann-Pick disease type C (NPC) AND
 - ii. The requested agent will be used for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) AND
 - iii. The requested agent will be used in combination with Miplyffa (arimoclomol) AND
3. Patient has had clinical benefit with the requested agent

Prior Authorization Group Description:

Tasimelteon Capsule PA

Drug Name(s)

Tasimelteon

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

- i. Patient has a diagnosis of Non-24-hour sleep-wake disorder AND
- ii. Patient is totally blind (i.e., no light perception) OR

B. BOTH of the following:

- i. Patient has a diagnosis of Smith-Magenis Syndrome (SMS) confirmed by the presence of ONE of the following genetic mutations:
 - A. A heterozygous deletion of 17p11.2 OR
 - B. A heterozygous pathogenic variant involving RAI1 AND
- ii. The requested agent is being used to treat nighttime sleep disturbances associated with SMS

Age Restriction:

For diagnosis of Non-24-hour sleep-wake disorder, patient is 18 years of age or over. For diagnosis of Smith-Magenis Syndrome (SMS), patient is 16 years of age or over.

Prescriber Restrictions:

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist, sleep specialist, psychiatrist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Teriparatide PA

Drug Name(s)

Bonsity

Teriparatide

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has ONE of the following:
 - A. Postmenopausal osteoporosis OR
 - B. Patient's sex is male with primary or hypogonadal osteoporosis OR
 - C. Osteoporosis with sustained systemic glucocorticoid therapy AND
2. Patient's diagnosis was confirmed by ONE of the following:
 - A. A fragility fracture in the hip or spine OR
 - B. A T-score of -2.5 or lower OR
 - C. A T-score of -1.0 to -2.5 AND ONE of the following:
 - i. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
 - ii. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
 - iii. A FRAX 10-year probability of hip fracture of 3% or greater AND
3. ONE of the following:
 - A. Patient is at high fracture risk as defined by ONE of the following:
 - i. Patient had a recent fracture (within the past 12 months) OR
 - ii. Patient had fractures while on FDA approved osteoporosis therapy OR
 - iii. Patient has had multiple fractures OR
 - iv. Patient had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
 - v. Patient has a very low T-score (less than -2.5) OR
 - vi. Patient is at high risk for falls or has a history of injurious falls OR
 - vii. Patient has a high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 20%, hip fracture greater than 3%) or by other validated fracture risk algorithm OR
 - B. ONE of the following:
 - i. Patient has tried and had an inadequate response to a bisphosphonate OR
 - ii. Patient has an intolerance or hypersensitivity to a bisphosphonate OR
 - iii. Patient has an FDA labeled contraindication to a bisphosphonate AND
4. Patient will NOT be using the requested agent in combination with a bisphosphonate, denosumab (e.g., Prolia, Xgeva), romosozumab-aqqg, or another parathyroid hormone analog (e.g., abaloparatide) for the requested indication AND

Criteria continues: see Other Criteria

Age Restriction:

Prescriber Restrictions:

Coverage Duration:

No prior teriparatide and/or Tymlos use approve 2 years, Prior use - see Other Criteria

Other Criteria:

5. The requested dose is within FDA labeled dosing for the requested indication AND

6. ONE of the following:

A. Patient has never received treatment with teriparatide or Tymlos (abaloparatide) OR

B. Patient has been previously treated with teriparatide or Tymlos (abaloparatide) AND ONE of the following:

i. The total cumulative duration of treatment with teriparatide and Tymlos (abaloparatide) has NOT exceeded 2 years OR

ii. Patient has received 2 years or more of treatment with teriparatide, or a combination of teriparatide and Tymlos (abaloparatide), and remains at or has returned to having a high risk for fracture

Prior teriparatide and/or Tymlos use approve remainder of 2 years of total cumulative therapy. Approve 1 year if patient has received 2 years or more teriparatide or a combination of teriparatide and Tymlos (abaloparatide)

Prior Authorization Group Description:

Tetrabenazine PA

Drug Name(s)

Tetrabenazine

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require ALL of the following:

1. ONE of the following:

- A. Patient has a diagnosis of chorea associated with Huntington's disease OR
- B. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

- A. Patient does NOT have a current diagnosis of depression OR
- B. Patient has a current diagnosis of depression and is being treated for depression AND

3. ONE of the following:

- A. Patient does NOT have a diagnosis of suicidal ideation and/or behavior OR
- B. Patient has a diagnosis of suicidal ideation and/or behavior and must NOT be actively suicidal AND

4. Patient will NOT be using the requested agent in combination with a monoamine oxidase inhibitor (MAOI) AND

5. Patient will NOT be using the requested agent in combination with reserpine

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Tobramycin neb PA

Drug Name(s)

Tobramycin Neb

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. Documentation has been provided that indicates the patient has a *Pseudomonas aeruginosa* respiratory infection AND
3. ONE of the following:
 - a. Patient is NOT currently (within the past 60 days) being treated with another inhaled antibiotic (e.g., inhaled aztreonam) OR
 - b. Patient is currently (within the past 60 days) being treated with another inhaled antibiotic (e.g., inhaled aztreonam) AND ONE of the following:
 - i. Prescriber has confirmed that the other inhaled antibiotic will be discontinued, and that therapy will be continued only with the requested agent OR
 - ii. Prescriber has provided information in support of another inhaled antibiotic therapy used concurrently with or alternating with (i.e., continuous alternating therapy) the requested agent

Drug is also subject to Part B versus Part D review.

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Topical Diclofenac 3% Gel PA

Drug Name(s)

Diclofenac Sodium Gel 3%

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require the following:

1. Patient has a diagnosis of actinic keratosis (AK)

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 3 months

Other Criteria:

Prior Authorization Group Description:

Topical NSAID PA – Pennsaid

Drug Name(s)

Diclofenac Sodium (Pennsaid)

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require the following:

1. ONE of the following:

- a. Patient has an FDA labeled indication for the requested agent OR
- b. Patient has an indication that is supported in CMS approved compendia for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

3 months for acute pain, 12 months for all other diagnoses

Other Criteria:

Prior Authorization Group Description:

Topical Retinoids PA – Tazarotene

Drug Name(s)

Tazarotene

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

Requested agent will be used for cosmetic purposes

Required Medical Information:

Criteria for approval require the following:

1. ONE of the following:

A. Patient has an FDA labeled indication for the requested agent OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Topical Retinoids PA – Tretinoin

Drug Name(s)

Tretinoin Cream, Gel

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

Requested agent will be used for cosmetic purposes

Required Medical Information:

Criteria for approval require the following:

1. ONE of the following:

A. Patient has an FDA labeled indication for the requested agent OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Trelstar PA

Drug Name(s)

Trelstar Mixject

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent OR
 - C. BOTH of the following:
 - i. Patient is NOT currently being treated with the requested agent AND
 - ii. Patient does NOT have any FDA labeled contraindications to the requested agent AND
3. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Trientine PA

Drug Name(s)

Trientine Hcl

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of Wilson's disease confirmed by ONE of the following:
 - A. Confirmation of genetic mutation of the ATP7B gene OR
 - B. Patient has TWO or more of the following:
 - i. Presence of hepatic abnormality (e.g., acute liver failure, cirrhosis, fatty liver)
 - ii. Presence of Kayser-Fleischer rings
 - iii. Serum ceruloplasmin level less than 20 mg/dL
 - iv. Basal urinary copper excretion greater than 40 mcg/24 hours or the testing laboratory's upper limit of normal
 - v. Hepatic parenchymal copper content greater than 40 mcg/g dry weight
 - vi. Presence of neurological symptoms (e.g., dystonia, hypertonia, rigidity with tremors, dysarthria, muscle spasms, dysphasia, polyneuropathy, dysautonomia) AND
2. ONE of the following:
 - A. Patient has tried and had an inadequate response to penicillamine OR
 - B. Patient has an intolerance or hypersensitivity to penicillamine OR
 - C. Patient has an FDA labeled contraindication to penicillamine

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Wilson's disease AND
3. Patient has had clinical benefit with the requested agent as evidenced by ONE of the following:
 - A. Improvement and/or stabilization in hepatic abnormality OR
 - B. Reduction in Kayser-Fleischer rings OR
 - C. Improvement and/or stabilization in neurological symptoms (e.g., dystonia, hypertonia, rigidity with tremors, dysarthria, muscle spasms, dysphasia, polyneuropathy, dysautonomia) OR
 - D. Basal urinary copper excretion greater than 200 mcg/24 hours

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist, neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Trikafta PA

Drug Name(s)

Trikafta

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. ONE of the following:
 - A. Patient has at least ONE variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein, as indicated in the FDA label, confirmed by genetic testing OR
 - B. Patient has another CFTR gene mutation(s) that is responsive to the requested agent, as indicated in the FDA label, confirmed by genetic testing AND
3. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of cystic fibrosis AND
3. Patient has had improvement or stabilization with the requested agent [e.g., improvement in FEV1 from baseline, increase in weight/BMI, improvement from baseline Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain score, improvements in respiratory symptoms (cough, sputum production, and difficulty breathing), and/or reduced number of pulmonary exacerbations] AND
4. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

Age Restriction:

Patient is within the FDA labeled age for the requested agent

Prescriber Restrictions:

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cystic fibrosis, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Trulicity PA

Drug Name(s)

Trulicity

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

Requested agent will be used for weight loss alone

Required Medical Information:

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent within the past 180 days OR
 - C. ALL of the following:
 - i. Patient does NOT have any FDA labeled contraindications to the requested agent AND
 - ii. Patient will NOT be using the requested agent in combination with another GLP-1 agonist agent, or an agent containing a GLP-1 agonist AND
 - iii. Patient will NOT be using the requested agent in combination with an agent containing a dipeptidyl peptidase-4 (DPP-4) inhibitor

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Tymlos PA

Drug Name(s)

Tymlos

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient (pt) has ONE of the following:
 - A. Postmenopausal osteoporosis OR
 - B. Pt's sex is male with osteoporosis AND
2. BOTH of the following:
 - A. Pt's diagnosis was confirmed by ONE of the following:
 - i. A fragility fracture in the hip or spine OR
 - ii. A T-score of -2.5 or lower OR
 - iii. A T-score of -1.0 to -2.5 AND ONE of the following:
 - a. A fragility fracture of proximal humerus, pelvis, or distal forearm OR
 - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
 - c. A FRAX 10-year probability of hip fracture of 3% or greater AND
 - B. ONE of the following:
 - i. Pt is at a very high fracture risk as defined by ONE of the following:
 - a. Pt had a recent fracture (within the past 12 months) OR
 - b. Pt had fractures while on FDA approved osteoporosis therapy OR
 - c. Pt has had multiple fractures OR
 - d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
 - e. Pt has a very low T-score (less than -3.0) OR
 - f. Pt is at high risk for falls or has a history of injurious falls OR
 - g. Pt has a very high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%) or by other validated fracture risk algorithm OR
 - ii. ONE of the following:
 - a. Pt has tried and had an inadequate response to a bisphosphonate OR
 - b. Pt has an intolerance or hypersensitivity to a bisphosphonate OR
 - c. Pt has an FDA labeled contraindication to a bisphosphonate AND
3. Pt will NOT be using the requested agent in combination with a bisphosphonate, denosumab (e.g., Prolia, Xgeva), romosozumab-aqqg, or another parathyroid hormone analog (e.g., teriparatide) for the requested indication AND
4. The requested dose is within FDA labeled dosing for the requested indication AND
5. The total cumulative duration of treatment with teriparatide and Tymlos (abaloparatide) has not exceeded 2 years

Age Restriction:

Prescriber Restrictions:

Coverage Duration:

No prior Tymlos and/or teriparatide use approve 2 years, Prior use - see Other Criteria

Other Criteria:

Prior Tymlos and/or teriparatide use approve remainder of 2 years of total cumulative therapy

Prior Authorization Group Description:

Urea Cycle Disorders PA - Sodium Phenylbutyrate

Drug Name(s)

Sodium Phenylbutyrate

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of ONE of the following:
 - a. Urea cycle disorder with neonatal-onset involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase OR
 - b. Urea cycle disorder with late-onset and history of hyperammonemic encephalopathy involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase AND
2. The requested dose is within FDA labeled dosing for the requested indication

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., geneticist, metabolic disorders) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Valchlor PA

Drug Name(s)

Valchlor

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent OR
 - C. BOTH of the following:
 - i. ONE of the following:
 - a. BOTH of the following:
 1. Patient has a diagnosis of Stage IA or IB mycosis fungoides-type cutaneous T-cell lymphoma AND
 2. Patient's medication history indicates use of at least ONE prior skin-directed therapy (e.g., topical corticosteroid) OR
 - b. Patient has an indication that is supported in CMS approved compendia for the requested agent AND
 - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, oncologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
3. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent OR
 - C. BOTH of the following:
 - i. Patient has had clinical benefit with the requested agent AND
 - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, oncologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Age Restriction:

Prescriber Restrictions:

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Veozah PA

Drug Name(s)

Veozah

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Voriconazole PA

Drug Name(s)

Voriconazole

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of invasive *Aspergillus* OR
- B. Patient has a serious infection caused by *Scedosporium apiospermum* or *Fusarium* species OR
- C. BOTH of the following:
 - i. ONE of the following:
 - 1. Patient has a diagnosis of esophageal candidiasis OR
 - 2. Patient has a diagnosis of candidemia in nonneutropenic patient OR
 - 3. Patient has a diagnosis of other deep tissue *Candida* infections AND
 - ii. ONE of the following:
 - 1. Patient has tried and had an inadequate response to fluconazole or an alternative antifungal agent OR
 - 2. Patient has an intolerance or hypersensitivity to fluconazole or an alternative antifungal agent OR
 - 3. Patient has an FDA labeled contraindication to fluconazole or an alternative antifungal agent OR
- D. Patient has a diagnosis of blastomycosis AND ONE of the following:
 - i. Patient has tried and had an inadequate response to itraconazole OR
 - ii. Patient has an intolerance or hypersensitivity to itraconazole OR
 - iii. Patient has an FDA labeled contraindication to itraconazole OR
- E. The requested agent is being prescribed for prophylaxis of invasive *Aspergillus* or *Candida* AND patient is severely immunocompromised, such as a hematopoietic stem cell transplant [HSCT] recipient, or hematologic malignancy with prolonged neutropenia from chemotherapy, or is a high-risk solid organ (lung, heart-lung, liver, pancreas, small bowel) transplant patient, or long term use of high dose corticosteroids (greater than 1 mg/kg/day of prednisone or equivalent) OR
- F. Patient has another indication that is supported in CMS approved compendia for the requested agent

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be 1 month for esophageal candidiasis, 6 months for all other indications

Other Criteria:

Criteria for renewal approval require BOTH of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
 - A. Patient has a diagnosis of invasive Aspergillus, a serious infection caused by *Scedosporium apiospermum* or *Fusarium* species, esophageal candidiasis, candidemia in nonneutropenic patient, other deep tissue *Candida* infections, or blastomycosis and patient has continued indicators of active disease (e.g., biomarkers in serum assay, microbiologic cultures, radiographic evidence) OR
 - B. The requested agent is being prescribed for prophylaxis of invasive Aspergillus or *Candida* and patient continues to be severely immunocompromised, such as a hematopoietic stem cell transplant [HSCT] recipient, or hematologic malignancy with prolonged neutropenia from chemotherapy, or is a high-risk solid organ (lung, heart-lung, liver, pancreas, small bowel) transplant patient, or long term use of high dose corticosteroids (greater than 1 mg/kg/day of prednisone or equivalent) OR
 - C. BOTH of the following:
 - i. Patient has another indication that is supported in CMS approved compendia for the requested agent AND
 - ii. Patient has had clinical benefit with the requested agent

Prior Authorization Group Description:

Vosevi PA

Drug Name(s)

Vosevi

Indications:

All Medically-Accepted Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of hepatitis C confirmed by serological markers AND
2. Prescriber has screened the patient for current or prior hepatitis B viral (HBV) infection and if positive, will monitor the patient for HBV flare-up or reactivation during and after treatment with the requested agent AND
3. The requested agent will be used in a treatment regimen and length of therapy that is supported in FDA approved labeling or AASLD/IDSA guidelines for the patient's diagnosis and genotype AND
4. The requested dose is within FDA labeled dosing or supported in AASLD/IDSA guideline dosing for the requested indication AND
5. If genotype 1, the patient's subtype has been identified and provided

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist or infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Duration of therapy: Based on FDA approved labeling or AASLD/IDSA guideline supported

Other Criteria:

Prior Authorization Group Description:

Vowst PA

Drug Name(s)

Vowst

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. The requested agent will be used to prevent the recurrence of Clostridioides difficile infection (CDI) AND
2. Patient has had a confirmed diagnosis of recurrent CDI as defined by greater than or equal to 3 episodes of CDI in a 12 month period AND
3. Patient has completed a standard of care antibiotic regimen (e.g., vancomycin, fidaxomicin) for recurrent CDI at least 2 to 4 days before initiating treatment with the requested agent AND
4. Patient will NOT be using the requested agent in combination with any antibiotic regimen for any indication

Age Restriction:

Patient is within the FDA labeled age for the requested agent

Prescriber Restrictions:

Prescriber is a specialist in the area of the patient's diagnosis (e.g., infectious disease, gastroenterologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Wyost PA

Drug Name(s)

Wyost

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require ALL of the following:

1. ONE of the following:

A. Patient has a diagnosis of multiple myeloma AND BOTH of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. ONE of the following:

1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR

2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR

3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR

B. Patient has a diagnosis of prostate cancer AND ALL of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. Patient has bone metastases AND

iii. ONE of the following:

1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR

2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR

3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR

Criteria continues: see Other Criteria

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

C. Patient has a solid tumor cancer diagnosis (e.g., thyroid, non-small cell lung, kidney cancer, or breast cancer) AND ALL of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. Patient has bone metastases AND

- iii. ONE of the following:
 - 1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
 - 2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
 - 3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR
- D. Patient has a diagnosis of giant cell tumor of bone AND ONE of the following:
 - i. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
 - ii. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
 - iii. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR
- E. Patient has a diagnosis of hypercalcemia of malignancy AND
- 2. Patient will NOT be using the requested agent in combination with another form of denosumab AND
- 3. The requested dose is within FDA labeled dosing for the requested indication

Prior Authorization Group Description:

Xdemvy PA

Drug Name(s)

Xdemvy

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has a diagnosis of Demodex blepharitis AND BOTH of the following:
 - A. Patient has ONE of the following signs of Demodex infestation:
 - i. Collarettes (cylindrical dandruff at the eyelash base) OR
 - ii. Lid margin erythema or edema OR
 - iii. Conjunctival injection OR
 - iv. Eyelash misdirection/irregularity AND
 - B. Patient has ONE of the following symptoms of Demodex infestation:
 - i. Blurred/fluctuating vision OR
 - ii. Discharge or crusting on lashes OR
 - iii. Dryness OR
 - iv. Foreign body sensation OR
 - v. Itching OR
 - vi. Pain/burning OR
 - vii. Watering/tearing

Age Restriction:**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., infectious disease, ophthalmologist, optometrist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 6 weeks

Other Criteria:

Prior Authorization Group Description:

Xermelo PA

Drug Name(s)

Xermelo

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of carcinoid syndrome diarrhea AND
2. Patient has tried and had an inadequate response to treatment with a somatostatin analog (e.g., octreotide) AND
3. The requested agent will be used in combination with a somatostatin analog (e.g., octreotide)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of carcinoid syndrome diarrhea AND
3. Patient has had clinical benefit with the requested agent (e.g., reduction in the average number of daily bowel movements) AND
4. The requested agent will be used in combination with a somatostatin analog (e.g., octreotide)

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Xifaxan 550 MG Tablet PA

Drug Name(s)

Xifaxan 550Mg

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for approval require the following:

1. Patient has ONE of the following:
 - a. A diagnosis of irritable bowel syndrome with diarrhea (IBS-D) OR
 - b. A diagnosis of hepatic encephalopathy [reduction in risk of overt hepatic encephalopathy (HE) recurrence]

Age Restriction:**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Xolair PA

Drug Name(s)

Xolair

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. ONE of the following:

A. Patient has a diagnosis of moderate to severe persistent asthma AND ALL of the following:

i. ONE of the following:

a. Patient is 6 to less than 12 years of age AND BOTH of the following:

1. Patient's pretreatment IgE level is 30 IU/mL to 1300 IU/mL AND

2. Patient's weight is 20 kg to 150 kg OR

b. Patient is 12 years of age or over AND BOTH of the following:

1. Patient's pretreatment IgE level is 30 IU/mL to 700 IU/mL AND

2. Patient's weight is 30 kg to 150 kg AND

ii. Allergic asthma has been confirmed by a positive skin test or in vitro reactivity test to a perennial aeroallergen AND

iii. ONE of the following:

a. Patient is currently being treated with AND will continue asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, theophylline) in combination with the requested agent OR

b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to an asthma control therapy OR

B. Patient has a diagnosis of chronic idiopathic urticaria (CSU) AND BOTH of the following:

i. Patient has had over 6 weeks of hives and itching AND

ii. ONE of the following:

a. Patient has tried and had an inadequate response to maximum tolerable H1 antihistamine therapy OR

b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to H1 antihistamine therapy OR

C. Patient has a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) AND BOTH of the following:

i. ONE of the following:

a. Patient has tried and had an inadequate response to an intranasal corticosteroid OR

b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to an intranasal corticosteroid AND

ii. ONE of the following:

a. The requested agent will be used in combination with an intranasal corticosteroid OR

- b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to an intranasal corticosteroid OR

Initial criteria continues: see Other Criteria

Age Restriction:

For diagnosis of moderate to severe persistent asthma, patient is 6 years of age or over. For diagnosis of chronic idiopathic urticaria (CSU), patient is 12 years of age or over. For diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP), patient is 18 years of age or over. For diagnosis of IgE-mediated food allergy, patient is 1 year of age or over.

Prescriber Restrictions:

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, hematologist, immunologist, oncologist, otolaryngologist, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be 6 months for initial, 12 months for renewal

Other Criteria:

- D. Patient has a diagnosis of IgE-mediated food allergy AND ALL of the following:
 - i. Patient is using the requested agent for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods AND
 - ii. IgE-mediated food allergy has been confirmed by an allergy diagnostic test (e.g., skin prick test, serum specific IgE test, oral food challenge) AND
 - iii. Patient will avoid known food allergens while treated with the requested agent AND
 - iv. The requested agent will NOT be used for the emergency treatment of allergic reactions, including anaphylaxis AND
- 2. Patient will NOT be using the requested agent in combination with Dupixent or an injectable Interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Fasenra, Nucala) for the requested indication AND
- 3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. ONE of the following:
 - A. Patient has a diagnosis of moderate to severe persistent asthma AND BOTH of the following:
 - i. Patient has had clinical benefit with the requested agent AND
 - ii. ONE of the following:
 - a. Patient is currently being treated with AND will continue asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, theophylline) in combination with the requested agent OR
 - b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to an asthma control therapy OR
 - B. Patient has a diagnosis of chronic idiopathic urticaria (CSU) AND the following:
 - a. Patient has had clinical benefit with the requested agent OR

- C. Patient has a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) AND the following:
 - a. Patient has had clinical benefit with the requested agent OR
- D. Patient has a diagnosis of IgE-mediated food allergy AND ALL of the following:
 - a. Patient is using the requested agent for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods AND
 - b. Patient has had clinical benefit with the requested agent AND
 - c. Patient will avoid known food allergens while treated with the requested agent AND
 - d. The requested agent will NOT be used for the emergency treatment of allergic reactions, including anaphylaxis AND
- 3. Patient will NOT be using the requested agent in combination with Dupixent or an injectable interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Fasenra, Nucala) for the requested indication AND
- 4. The requested dose is within FDA labeled dosing for the requested indication

Prior Authorization Group Description:

Zokinvy PA

Drug Name(s)

Zokinvy

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

Required Medical Information:

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

- i. Patient has a diagnosis of Hutchinson-Gilford progeria syndrome (HGPS) AND
- ii. Genetic testing has confirmed a pathogenic variant in the LMNA gene that results in production of progerin OR

B. Patient has a diagnosis of processing-deficient progeroid laminopathy AND ONE of the following:

- i. Genetic testing has confirmed heterozygous LMNA mutation with progerin-like protein accumulation OR
- ii. Genetic testing has confirmed homozygous or compound heterozygous ZMPSTE24 mutations

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. Patient has a diagnosis of ONE of the following:

- A. Hutchinson-Gilford progeria syndrome (HGPS) OR
- B. Processing-deficient progeroid laminopathies with either: heterozygous LMNA mutation with progerin-like protein accumulation OR homozygous or compound heterozygous ZMPSTE24 mutations AND

3. Patient has had clinical benefit with the requested agent

Age Restriction:

Patient is within the FDA labeled age for the requested agent

Prescriber Restrictions:

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cardiologist, geneticist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Coverage Duration:

Approval will be for 12 months

Other Criteria:

Prior Authorization Group Description:

Ztalmy PA

Drug Name(s)

Ztalmy

Indications:

All FDA-Approved Indications.

Off-Label Uses:**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) AND
2. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent OR
 - C. BOTH of the following:
 - i. Patient's diagnosis has been confirmed with genetic testing indicating variant in CDKL5 gene AND
 - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) AND
3. ONE of the following:
 - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
 - B. Prescriber states the patient is currently being treated with the requested agent OR
 - C. BOTH of the following:
 - i. Patient has had clinical benefit with the requested agent AND
 - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Age Restriction:

Patient is within the FDA labeled age for the requested agent

Prescriber Restrictions:**Coverage Duration:**

Approval will be for 12 months

Other Criteria:



Health Insurance Plan of Greater New York (HIP) is an HMO plan with a Medicare contract and a HMO D-SNP plan with a Medicare contract and a contract with the New York State Department of Health. Enrollment in HIP depends on contract renewal. HIP is an EmblemHealth company. EmblemHealth Plan, Inc. is a PPO plan with a Medicare contract. Enrollment in EmblemHealth Plan, Inc. depends on contract renewal.

Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

Beneficiaries must use network pharmacies to access their premium and/or copayment/coinsurance may change on January 1, 2027. The formulary and pharmacy network may change at any time. You will receive notice when necessary.

This document includes EmblemHealth Medicare HMO/PPO partial formulary as of July 1, 2026. For a complete, updated formulary, please visit our Web site at www.emblemhealth.com/medicare or call the Customer Service number below.

EmblemHealth Medicare HMO at **877-344-7364** (TTY users should call **711**). From Oct. 1 to March 31, you can call us seven days a week from 8 a.m. to 8 p.m. From April 1 to Sept. 30, you can call us Monday through Saturday from 8 a.m. to 8 p.m. or visit **emblemhealth.com/medicare**.

26229 v16